

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	27	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	28	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	29	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS EXPRESS	29	JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:44:44 ON 26 JUL 2007

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:44:56 ON 26 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2007 HIGHEST RN 943407-83-8

DICTIONARY FILE UPDATES: 25 JUL 2007 HIGHEST RN 943407-83-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10531889\10531889a.str



chain nodes :
 7 14 15 16 17 18 19 23 25
 ring nodes :
 1 2 3 4 5 6 8 9 10 11 12 13
 chain bonds :
 1-18 2-19 3-15 4-16 5-17 6-7 7-8 9-25 10-23 12-14
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
 exact/norm bonds :
 1-18 2-19 3-15 4-16 5-17 6-7 7-8 10-23 12-14
 exact bonds :
 9-25
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

G1:H,X,CN

G2:H,Cl,F

G3:H,OH,X,CF3,Ak,Cb


Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
 19:CLASS 23:CLASS 25:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H, X, CN

G2 H, Cl, F

G3 H, OH, X, CF₃, Ak, Cb

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:45:17 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 416 TO ITERATE

100.0% PROCESSED 416 ITERATIONS

18 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 7097 TO 9543

PROJECTED ANSWERS: 106 TO 614

L2 18 SEA SSS SAM L1

=> d scan


L2 18 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-(3,4-dichlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9C1)
 MF C22 H16 Cl2 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 18 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-[4-(dimethylamino)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9C1)
 MF C24 H21 N7 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss full
FULL SEARCH INITIATED 11:45:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 8199 TO ITERATE

100.0% PROCESSED 8199 ITERATIONS 411 ANSWERS
SEARCH TIME: 00.00.01

L3 411 SEA SSS FUL L1

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	172.55	172.76

FILE 'CAPLUS' ENTERED AT 11:46:03 ON 26 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jul 2007 VOL 147 ISS 5
FILE LAST UPDATED: 25 Jul 2007 (20070725/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3
L4 35 L3

=> d scan

L4 35 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN
 IC ICM C07D
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 TI Preparation of diaminopyrimidines as anticancer drugs.
 ST aminopyrimidine prepn anticancer; pyrimidinamine pyridyloxyphenylamino
 indolyl prepn cancer treatment
 IT Antitumor agents
 Drug delivery systems
 Human
 (preparation of diaminopyrimidines as anticancer drugs)
 IT Neoplasm
 (treatment; preparation of diaminopyrimidines as anticancer drugs)
 IT 912471-74-0P 912471-75-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of diaminopyrimidines as anticancer drugs)
 IT 56-05-3, 4,6-Dichloropyrimidin-2-amine 110-91-8, Morpholine, reactions
 123-30-8, 4-Aminophenol 19235-89-3, 4-Chloropyridine-2-carbonitrile
 144104-59-6, 1H-Indol-5-ylboronic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of diaminopyrimidines as anticancer drugs)
 IT 630125-69-8P 850250-76-9P 871240-10-7P
 912471-76-2P 912472-79-8P 912472-80-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of diaminopyrimidines as anticancer drugs)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l4 ibib abs hitstr


MISSING OPERATOR L4 IBIB

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l4 1-35 ibib abs hitstr


L4 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2007:510223 CAPLUS
DOCUMENT NUMBER: 146:501071
TITLE: Preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of kinases
INVENTOR(S): Cao, Jon Jiaquor Hood, John; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Noronha, Glenn; Pathak, Ved; Renick, Joel; Soll, Richard M.; Zeng, Binqi
PATENT ASSIGNEE(S): Targeen, Inc., USA
SOURCE: PCT Int. Appl., 336pp., which
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007053452	A1	20070510	WO 2006-US42044	20061026
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.: US 2005-732629P P 20051101 US 2006-838003P P 20060815				
OTHER SOURCE(S): MARPAT 146:501071				
GI				



L4 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2006:1097641 CAPLUS
DOCUMENT NUMBER: 145:419172
TITLE: Preparation of diaminopyrimidines as anticancer drugs.
INVENTOR(S): Nagarathnam, Dhanapalan; Chen, Yuanwei; Fu, Wenlang; Wang, Ming; Bierer, Donald; Brands, Michael; Wang, Yamin; Bear, Brian R.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 42pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110447	A2	20061019	WO 2006-US12828	20060407
WO 2006110447	A3	20070118		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.: US 2005-669461P P 20050408				
OTHER SOURCE(S): MARPAT 145:419172				
GI				



AB Title compds. [1: A = O, NR; R = H, alkyl; D = N, CH; R2 = (substituted) bicyclic aryl; R3 = Cl, Br, cyano, aminocarbonyl, alkylaminocarbonyl, alkyl, CF3; R4 = H, alkyl; R5 = H, halo], were prepared. Thus, 6-chloro-N4-[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine (preparation given), 1H-indol-5-ylboronic acid, PdCl2(dppf), dimethylacetamide, and aqueous K2CO3 were heated together at 120° overnight to give 6-(1H-indol-5-yl)-N4-[4-[[2-(trifluoromethyl)pyridin-4-

L4 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


AB The title compds. I [X = a bond, C(O), SO2, CH2; Y = a bond, NR9; or X and Y taken together is a bond; R1, R2 = H, alkyl, cycloalkyl, etc.; or R1 and R2 taken together is a bond; or R1 and R2 taken together form (CH2)m, (CH2)r(CH2)m, (CH2)rO(CH2)m, etc.; p, q, r, n, m = 0-6; R9 = H, alkyl, cycloalkyl, etc.; G0 = N, O, H, CH; R3, R4 = H, alkyl, hydroxyalkyl, etc.; G = N or CR6; R5 = Me; Q = (un)substituted Ph, indolyl, indazolyl, etc.; with provisoes) that are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases, were prepared. E.g., a 2-step synthesis of II, starting from 4-chloropyrimidin-2-ylamine and 4-methoxyphenylamine, was given. Exemplified compds. I were tested for inhibition of JAK2 kinase (data given). The invention also relates to pharmaceutical composition comprising the compound I alone or in combination with other therapeutic agents.

IT 500863-19-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of JAK

kinases for treating diseases)

RN 500863-19-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-methoxyphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
v[oxy]phenyl]pyrimidine-2,4-diamine. The latter showed an IC50

≤500 nM in the HCT116 cytotoxic activity assay.


IT 850250-76-9P 871240-10-7P 912471-76-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diaminopyrimidines as anticancer drugs)


RN 850250-76-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9C1) (CA INDEX NAME)




RN 871240-10-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[[2-methyl-4-pyridinyl]oxy]phenyl]- (9C1) (CA INDEX NAME)




RN 912471-76-2 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-chloro-4-pyrimidinyl]amino]phenoxy]- (9C1) (CA INDEX NAME)




L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 yl)amino]phenoxy]pyridin-2-yl)methyl]-4-fluorobenzamide
 850247-32-4P, 3-[[4-[(2-Amino-6-phenylpyrimidin-4-
 yl)amino]phenoxy]pyridin-2-yl)methyl]-1,1-diethylurea 850247-33-5P
 850247-34-6P, N'-[4-[[2-[(4,5-Dihydro-1H-imidazol-2-yl)pyridin-4-
 yl)oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-35-7P,
 4-[[4-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy]pyridine-2-carboxylic
 acid (2-hydroxyethyl)amide 850247-36-8P, 6-Phenyl-N'-[4-[[2-[(1H-
 tetrazol-5-yl)pyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine
 850247-37-9P, N'-[4-[[2-[(4,5-Dihydro-1H-imidazol-2-yl)pyridin-4-
 yl)oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850247-39-1P,
 (S)-N'-[4-[[2-[(2-Methoxymethylpyrrolidin-1-yl)pyridin-4-yl)oxy]phenyl]-6-
 phenylpyrimidine-2,4-diamine 850247-42-6P 850247-43-7P
 , N'-[4-[[2-Aminopyridin-4-yl)oxy]phenyl]-6-phenylpyrimidine-2,4-diamine
 850247-44-8P, 4-[[2-Amino-6-[[4-[(2-chloropyridin-4-
 yl)oxy]phenyl]amino]pyrimidin-4-yl]pheno] 850247-45-9P,
 (3E)-4-[[4-[[2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy]pyridin-2-
 yl]but-3-en-1-ol 850247-48-2P 850252-00-5P,
 4-[[4-[(2-Amino-6-phenylpyrimidin-4-yl)amino]-3-fluorophenoxy]pyridine-2-
 carbonitrile hydrochloride 871240-05-0P, 6-(2,6-Dimethylphenyl)-
 N'-[4-[[2-(trifluoromethyl)pyridin-4-yl)oxy]phenyl]pyrimidine-2,4-diamine
 871240-08-3P, 6-Phenyl-N'-[4-[[2-(trifluoromethyl)pyrimidin-4-
 yl)oxy]phenyl]pyrimidine-2,4-diamine 910215-42-8P,
 2-Amino-N'-[4-[[2-amino-6-[[4-[(2-trifluoromethyl)pyridin-4-
 yl)oxy]phenyl]amino]pyrimidin-4-yl]phenyl]-3-hydroxypropionamide
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of pyrimidine derivs. for treatment of hyperproliferative
 disorders)
 RN 850246-99-0 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(2-ethyl-4-pyridinyl)oxy]phenyl]-6-phenyl-
 (9CI) (CA INDEX NAME)




RN 850247-00-6 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-phenyl-
 (9CI) (CA INDEX NAME)




RN 850247-03-9 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(3,5-difluoro-4-pyridinyl)oxy]phenyl]-6-
 phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850247-11-9 CAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 850247-13-1 CAPLUS
 CN Piperazine, 1-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl- (9CI) (CA INDEX NAME)




RN 850247-16-4 CAPLUS
 CN Piperazine, 1-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl- (9CI) (CA INDEX NAME)




RN 850247-21-1 CAPLUS
 CN Urea, N'-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850247-04-0 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(4-nitrophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-05-1 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-
 phenyl- (9CI) (CA INDEX NAME)




RN 850247-09-5 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(4-chlorophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-10-8 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(4-methoxyphenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850247-27-7 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(1-oxido-2-(trifluoromethyl)-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-29-9 CAPLUS
 CN Methanesulfonamide, N-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl- (9CI) (CA INDEX NAME)



RN 850247-31-3 CAPLUS
 CN Benzamide, N-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 850247-32-4 CAPLUS
 CN Urea, N'-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 850247-33-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 850247-34-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(1-methylethyl)amino]methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-35-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 850247-36-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[(2-(1H-tetrazol-5-yl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850247-37-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4,5-dihydro-1H-imidazol-2-yl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-39-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 850247-42-6 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[(2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 850247-43-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-amino-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-44-8 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[(2-chloro-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850247-45-9 CAPLUS
CN 3-Buten-1-ol, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 850247-48-2 CAPLUS
CN 2-Pyridinemethanol, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, (3E)- (9CI) (CA INDEX NAME)


mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
CM 1
CRN 850247-47-1
CMF C22 H19 N5 O2



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 850252-00-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]-3-fluorophenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl


RN 871240-05-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,6-dimethylphenyl)-N4-[4-[(2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 871240-08-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9C1) (CA INDEX NAME)




RN 910215-42-8 CAPLUS
CN Propanamide, 2-amino-N-[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]-3-hydroxy- (9C1) (CA INDEX NAME)



IT 850247-52-8, N'-[4-[[4-Bromopyridin-2-yl]oxy]phenyl]-6-phenylpyrimidine-2,4-diamine 850248-80-5, 6-(4-Aminophenyl)-N'-[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. for treatment of hyperproliferative disorders)

RN 850247-52-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-bromo-2-pyridinyl]oxy]phenyl]-6-phenyl- (9C1) (CA INDEX NAME)



RN 850248-80-5 CAPLUS

ACCESSION NUMBER: 2006:600888 CAPLUS
DOCUMENT NUMBER: 145:83219
TITLE: Preparation of 4-phenoxy-7-azaindoles as rho kinase II inhibitors
INVENTOR(S): Schirok, Hartmut; Stasch, Johannes-Peter; Kast, Raimund; Figueroa Perez, Santiago; Muentert, Klaus; Gnoth, Mark Jean; Radtke, Martin; Lang, Dieter; Mittendorf, Joachim
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: Ger. Offen., 24 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004060752	A1	20060622	DE 2004-102004060752	20041215
PRIORITY APPLN. INFO.:			DE 2004-102004060752	20041215


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = CF3; R2 = H, F; R3 = H, Cl, CF3, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, coupling of 2-amino-4-chloropyrimidine and aniline II afforded phenoxyazaindole III in 53% yield. In rho kinase II inhibition assays, 4-examples of compds. I exhibited IC50 values ranging from 0.7-0.9 nM.

IT 892414-37-8P 892414-38-9P 892414-39-0P
892414-40-3P 892414-41-4P 892414-42-5P
892414-43-6P 892414-44-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-phenoxy-7-azaindoles as rho kinase II inhibitors)


RN 892414-37-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (9C1) (CA INDEX NAME)

CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9C1) (CA INDEX NAME)




IT 850250-76-9P, 6-Chloro-N'-[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine 871240-10-7P, 6-Chloro-N'-[4-[[2-methylpyridin-4-yl]oxy]phenyl]pyrimidine-2,4-diamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. for treatment of hyperproliferative disorders)


RN 850250-76-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9C1) (CA INDEX NAME)




RN 871240-10-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9C1) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




RN 892414-38-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-(trifluoromethyl)- (9C1) (CA INDEX NAME)




RN 892414-39-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (9C1) (CA INDEX NAME)




RN 892414-40-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 892414-41-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 892414-42-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 892414-43-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 892414-44-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 2006:301346 CAPLUS
DOCUMENT NUMBER: 144:350708
TITLE: Novel pyrimidine compounds, process for their preparation, pharmaceutical compositions, and their use as antiinflammatory, cytotoxic, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases
INVENTOR(S): Kallada, Srinivas; Padakanti, Srinivas; Kumar Swamy, Nalivela; Yaleswarapu, Koteswar Rao; Alexander, Christopher W.; Khanna, Ish Kumar; Iqbal, Javed; Pillarisetti, Sivaram; Pal, Manojit; Barange, Deepak
PATENT ASSIGNEE(S): Reddy US Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 336 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006034473	A2	20060330	WO 2005-US34243	20050923
WO 2006034473	A3	20061214		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005286592	A1	20060330	AU 2005-286592	20050923
CA 2581454	A1	20060330	CA 2005-2581454	20050923
US 2006084644	A1	20060420	US 2005-234257	20050923
US 2006084645	A1	20060420	US 2005-234695	20050923
EP 1796673	A2	20070620	EP 2005-799686	20050923
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LJ, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HB, MK, YU				
PRIORITY APPLN. INFO.:			US 2004-612374P	P 20040923
			WO 2005-US34243	W 20050923
OTHER SOURCE(S):			MARPAT 144:350708	
GI				




AB The invention provides heterocyclic compds., particularly substituted pyrimidines of formula I, methods and compns. for making and using these heterocyclic compds., and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan. Compds. of formula I wherein R₁, R₂ and R₄ are independently (un)substituted (hetero)aryl or (un)substituted heterocyclyl; and their pharmaceutically acceptable salts, prodrugs, diastereoisomeric mixts., enantiomers, tautomers, and racemic mixts. thereof are claimed in this invention. Example compound II was prepared by acylation of 4-methoxyacetophenone with di-Et carbonate; the resulting Et 4-methoxybenzoylacetate underwent cyclization with guanidine carbonate to give 2-amino-6-(4-methoxyphenyl)pyrimidin-4-ol, which was converted to 4-chloro-6-(methoxyphenyl)pyrimidin-2-ylamine, which underwent amination with 3-chloro-4-methoxyaniline to give compound II. The invention compds. were evaluated for their antiinflammatory, proliferative, cardiovascular, and immunosuppressive activity (no data).

IT 881193-01-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)
 RN 881193-01-7 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




IT 843608-32-2P 881193-00-6P 881193-02-8P
 881193-03-9P 881193-04-0P 881193-05-1P
 881193-06-2P 881193-07-3P 881193-10-8P
 881194-21-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (drug candidate; prepn. of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)
 RN 843608-32-2 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 881193-00-6 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 881193-02-8 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 881193-03-9 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 881193-04-0 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 881193-05-1 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-methylthiophenyl)- (9CI) (CA INDEX NAME)




RN 881193-06-2 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(3-fluoro-4-methoxyphenyl)-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 881193-07-3 CAPLUS
 CN Phenol, 4-[[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 881193-10-8 CAPLUS
 CN Phenol, 4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 881194-21-4 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-methylsulfonylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2005:1313901 CAPLUS
DOCUMENT NUMBER: 144:51598
TITLE: Preparation of amino-substituted pyrimidines as
antitumor agents
INVENTOR(S): Dixon, Julie A.; Nagarathnam, Dhanapalan; Zhang, Lei;
Wang, Chunguang; Yi, Lin; Chen, Yuanwei; Chen,
Jianqing; Bear, Brian R.; Brands, Michael; Hillisch,
Alexander; Bierer, Donald; Wang, Ming; Fu, Wenlang;
Hentemann, Martin F.; Bullion, Ann-Marie; Patel, Manoj
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 182 pp., Cont.-in-part of Appl.
No. PCT/US04/033430.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005277640	A1	20051215	US 2005-78681	20050310
WO 200503507	A2	20050421	WO 2004-033430	20041008
WO 200503507	A3	20060831		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW,
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-510804P P 20031010
WO 2004-US33430 A2 20041008

OTHER SOURCE(S): CASREACT 144:51598; MARPAT 144:51598
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [R1 = H, alkyl, cyclopropyl; R2 = alkyl, cyclopropyl,
O-alkyl, etc.; R3 = H, halo; M = CH, N; L = carbonyl, O, (un)substituted
alkylenyl, etc.; J and Y independently = substituted aryl, heteroaryl; A =
halo, CF3, CN, etc.; m = 0-2] and their pharmaceutically acceptable salts,
are prepared and disclosed as useful antitumor agents. Thus, coupling
6-chloro-N4-[4-[(2-(trifluoromethyl)pyridin-4-yl)oxy]phenyl]pyrimidine-2,4-
diamine with 1,3-dimethylphenylboronic acid afforded 56a II which showed
IC50 of 62 nM in test for cytotoxic activity on HCT-116 cells.

IT 850247-06-2P 850247-12-0P 850247-26-6P
850247-28-8P 850247-38-0P 850247-41-5P
850248-80-5P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation of amino-substituted pyrimidines as antitumor agents)

RN 850247-06-2 CAPLUS


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 850247-41-5 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850248-80-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(aminophenyl)-N4-[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)




IT 850246-99-0P 850247-00-6P 850247-03-9P
850247-04-0P 850247-05-1P 850247-09-5P
850247-10-8P 850247-11-9P 850247-14-2P
850247-15-3P 850247-17-5P 850247-21-1P
850247-27-7P 850247-30-2P 850247-31-3P
850247-32-4P 850247-33-5P 850247-34-6P
850247-36-7P 850247-36-8P 850247-37-9P
850247-39-1P 850247-40-4P 850247-42-6P
850247-43-7P 850247-44-8P 850247-46-0P
850247-48-2P 850247-50-6P 850247-51-7P
850247-52-8P 850247-54-0P 850247-55-1P
850247-56-2P 850247-57-3P 850247-59-4P
850247-59-5P 850247-60-8P 850247-61-9P
850247-63-1P 850247-65-3P 850247-68-6P
850247-70-0P 850247-71-1P 850247-73-3P
850247-75-5P 850247-76-6P 850247-77-7P
850247-78-8P 850247-80-2P 850247-86-8P
850247-88-0P 850247-91-5P 850247-94-8P
850247-97-1P 850248-00-9P 850248-03-2P
850248-04-3P 850248-05-4P 850248-07-6P
850248-08-7P 850248-09-8P 850248-10-1P
850248-11-2P 850248-12-3P 850248-13-4P


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
CN 2-Pyridinecarbonitrile, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850247-12-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-26-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(trifluoromethyl)pyridin-4-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850247-28-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-38-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(chloro-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


850248-14-5P 850248-15-6P 850248-16-7P
850248-17-8P 850248-18-9P 850248-20-3P
850248-21-4P 850248-22-5P 850248-23-6P
850248-24-7P 850248-41-8P 850248-43-0P
850248-45-2P 850248-46-3P 850248-47-4P
850248-48-5P 850248-49-6P 850248-50-9P
850248-51-0P 850248-52-1P 850248-53-2P
850248-54-3P 850248-55-4P 850248-56-5P
850248-57-6P 850248-58-7P 850248-59-8P
850248-61-2P 850248-62-3P 850248-63-4P
850248-65-6P 850248-67-8P 850248-68-9P
850248-69-0P 850248-70-3P 850248-71-4P
850248-72-5P 850248-73-6P 850248-74-7P
850248-75-8P 850248-76-9P 850248-77-0P
850248-78-1P 850248-79-2P 850248-81-6P
850248-82-7P 850248-83-8P 850248-84-9P
850248-85-0P 850248-86-1P 850248-87-2P
850248-88-3P 850248-89-4P 850248-90-7P
850248-91-8P 850248-92-9P 850248-93-0P
850248-95-2P 850248-96-3P 850248-98-5P
850249-00-2P 850249-01-3P 850249-02-4P
850249-03-5P 850249-05-7P 850249-06-8P
850249-08-0P 850249-09-1P 850249-10-4P
850249-12-6P 850249-13-7P 850249-14-8P
850249-15-9P 850249-16-0P 850249-17-1P
850249-18-2P 850249-20-6P 850249-21-7P
850249-22-8P 850249-23-9P 850249-24-0P
850249-25-1P 850249-26-2P 850249-27-3P
850249-28-4P 850249-31-9P 850249-32-0P
850249-33-1P 850249-35-3P 850249-38-6P
850249-40-0P 850249-42-2P 850249-44-4P
850249-45-5P 850249-47-7P 850249-48-8P
850249-54-6P 850249-57-9P 850249-59-1P
850249-61-5P 850249-63-7P 850249-64-8P
850249-70-6P 850249-73-9P 850249-75-1P
850249-77-3P 850249-78-4P 850249-79-5P
850249-80-8P 850249-81-9P 850249-82-0P
850249-83-1P 850249-84-2P 850249-85-3P
850249-87-5P 850249-88-6P 850249-89-7P
850249-91-1P 850249-92-2P 850249-93-3P
850249-95-5P 850249-96-6P 850249-97-7P
850249-98-8P 850249-99-9P 850250-00-9P
850250-01-0P 850250-02-1P 850250-03-2P
850250-04-3P 850250-06-5P 850250-07-6P
850250-08-7P 850250-09-8P 850250-10-1P
850250-11-2P 850250-12-3P 850250-13-4P
850250-14-5P 850250-15-6P 850250-18-9P
850250-40-7P 850250-41-8P 850250-42-9P
850250-43-0P 850250-44-1P 850250-45-2P
850250-46-3P 850250-47-4P 850250-49-6P
850250-50-9P 850250-51-0P 850250-52-1P
850250-53-2P 850250-54-3P 850250-55-4P
850250-57-6P 850250-58-7P 850250-59-8P
850250-60-1P 850250-61-2P 850250-81-6P
850252-00-5P 850252-01-6P 871240-05-0P
871240-08-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino-substituted pyrimidines as antitumor agents)


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 850246-99-0 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(2-ethyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-00-6 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-03-9 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(3,5-difluoro-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-04-0 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-(4-nitrophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-05-1 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 phenyl- (9CI) (CA INDEX NAME)




RN 850247-09-5 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-(4-methoxyphenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-10-8 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-(4-methoxyphenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-11-9 CAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[(4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 850247-14-2 CAPLUS
 CN Morpholine, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CM 1


CRN 850247-13-1
 CMF C26 H24 N6 O3



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 850247-15-3 CAPLUS
 CN 2-Pyridinecarboxamide, 4-[(4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 850247-17-5 CAPLUS
 CN Piperazine, 1-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-4-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
 CRN 850247-16-4
 CMF C27 H27 N7 O2


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 850247-21-1 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(2-[2-(4-morpholinyl)ethoxy]-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-27-7 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(1-oxido-2-(trifluoromethyl)-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-30-2 CAPLUS
 CN Methanesulfonamide, N-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 850247-29-9
CN C23 H22 N6 O3 S




CN 2
RN 76-05-1
CN C2 H F3 O2




RN 850247-31-3 CAPLUS
CN Benzanide, N-[[4-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 850247-32-4 CAPLUS
CN Urea, N'-[[4-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850247-37-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[4,5-dihydro-1H-imidazol-2-yl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-39-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[2-(methoxymethyl)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850247-40-4 CAPLUS
CN Propanamide, 2-amino-N-[[4-[[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 850247-33-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[4-[[2-(methoxymethyl)-1-pyrrolidinyl]-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 850247-34-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[1-methylethyl]amino]methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-35-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 850247-36-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[[4-[[2-(1H-tetrazol-5-yl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850247-42-6 CAPLUS
CN Sulfamic acid, 4-[[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 850247-43-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-amino-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-44-8 CAPLUS
CN Phenol, 4-[[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850247-46-0 CAPLUS
CN 3-Buten-1-ol, 4-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]-, (3E)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 850247-45-9
CMF C25 H23 N5 O2

Double bond geometry as shown.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 850247-48-2 CAPLUS
CN 2-Pyridinemethanol, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 850247-47-1
CMF C22 H19 N5 O2



CM 2

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 850247-53-9
CMF C21 H16 F N5 O




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 850247-55-1 CAPLUS
CN 2-(1H)-Pyridinone, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-56-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[(2-chloro-4-pyridinyl)oxy]-2-fluorophenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-57-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[2-fluoro-4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CRN 76-05-1
CMF C2 H F3 O2




RN 850247-50-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[[4-(5-pyrimidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850247-51-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-(4-aminophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-52-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[(4-bromo-2-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-54-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[(2-fluoro-4-pyridinyl)oxy]phenyl]-6-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850247-58-4 CAPLUS
CN Benzonitrile, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850247-59-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850247-60-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 850247-61-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(2-amino-6-(4-fluorophenyl)-4-pyrimidinyl)amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 850247-63-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-(4-fluorophenyl)-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-65-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[(2-amino-6-(4-fluorophenyl)-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850247-68-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

RN 850247-70-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-1-azabicyclo[2.2.2]oct-3-yl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1



CH 2

CRN 76-05-1
CHF C2 H F3 O2




RN 850247-75-5 CAPLUS
CN 3-Pyrrolidinol, 1-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-, (3R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 850247-74-4
CHF C26 H24 N6 O3


Absolute stereochemistry.



CH 2

CRN 76-05-1
CHF C2 H F3 O2

CRN 850247-69-7
CHF C29 H29 N7 O2




CH 2

CRN 76-05-1
CHF C2 H F3 O2



RN 850247-71-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2,3-dihydroxypropyl)- (9CI) (CA INDEX NAME)



RN 850247-73-3 CAPLUS
CN Pyrrolidine, 1-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-2-(methoxymethyl)-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 850247-72-2
CHF C28 H28 N6 O3


Absolute stereochemistry.




RN 850247-76-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-butoxy-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-77-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methoxyethoxy)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-78-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-(dimethylamino)ethoxy)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-80-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-ethoxy-4-pyridinyl)oxy]phenyl]-6-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 850247-79-9
CHF C23 H21 N5 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850247-86-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-28-8
CMF C22 H20 N6 O

CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 850247-88-0 CAPLUS
CN 1H-Imidazole-4-sulfonamide, N-[[4-[[2-amino-6-phenyl-4-



RN 850247-94-8 CAPLUS
CN 2-Propanesulfonamide, N-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-93-7
CMF C25 H26 N6 O3 S

CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 850247-97-1 CAPLUS
CN Benzenesulfonamide, N-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-96-0
CMF C28 H24 N6 O3 S

CM 1


CRN 850247-87-9
CMF C26 H24 N8 O3 S

CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 850247-91-5 CAPLUS
CN Ethanesulfonamide, N-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-90-4
CMF C24 H24 N6 O3 S

CM 2




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850248-00-9 CAPLUS
CN Benzenesulfonamide, N-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-4-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-99-3
CMF C29 H26 N6 O4 S

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 850248-03-2 CAPLUS
CN Benzene sulfonamide, N-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinylmethyl]-4-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-02-1
CMF C28 H23 F N6 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850248-04-3 CAPLUS
CN Urea, N'-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinylmethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 850248-05-4 CAPLUS


RN 850248-09-8 CAPLUS
CN Urea, N-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinylmethyl]-N',N'-diethyl-N-methyl- (9CI) (CA INDEX NAME)




RN 850248-10-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinylmethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 850248-11-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[(4-morpholinyl)-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-12-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[(1-piperidinyl)-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-13-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[(4-methyl-1-piperazinyl)-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-07-6 CAPLUS
CN Urea, [[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinylmethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-06-5
CMF C23 H21 N7 O2




CM 2



CRN 76-05-1
CMF C2 H F3 O2




RN 850248-08-7 CAPLUS
CN Urea, [[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinylmethyl]trimethyl- (9CI) (CA INDEX NAME)




RN 850248-14-5 CAPLUS
CN Ethanol, 2,2'-[[2-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-4-pyridinyl]imino]bis- (9CI) (CA INDEX NAME)



RN 850248-15-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[bis(2-methoxyethyl)amino]-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-16-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[1-ethylpropyl]amino]methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-17-8 CAPLUS


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(cyclohexylamino)methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-18-9 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-[(3,4-dichlorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-20-3 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 850248-21-4 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 850248-22-5 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850248-45-2 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-[(phenylmethyl)amino]-4-pyridinyl]oxy]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 850248-44-1
 CMF C28 H24 N6 O



CH 2


CRN 76-05-1
 CMF C2 H F3 O2




RN 850248-46-3 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850248-23-6 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-24-7 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-41-8 CAPLUS
 CN Ethanol, 2,2'-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]imino]bis- (9CI) (CA INDEX NAME)




RN 850248-43-0 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-[(1-(phenylmethyl)hydrazino)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850248-47-4 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(4-morpholinyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-48-5 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(4-methyl-1-piperazinyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-49-6 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(4-(2-methoxyethyl)-1-piperazinyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-50-9 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2-methoxyethyl)methylamino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)







RN 850248-51-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[2-(dimethylamino)ethyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-52-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-(1-piperidinyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-53-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[bis(2-methoxyethyl)amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-54-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[3-(diethylamino)propyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 850248-58-7 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850248-59-8 CAPLUS
CN 3-Pyrrolidinol, 1-[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 850248-61-2 CAPLUS
CN Butanoic acid, 4-[[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 850248-62-3 CAPLUS
CN Glycine, N-[[1,1-dimethylethoxy]carbonyl]-, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl ester (9CI) (CA INDEX NAME)



RN 850248-55-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)





RN 850248-56-5 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(4-morpholinyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 850248-57-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[3-(dimethylamino)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850248-63-4 CAPLUS
CN Glycine, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 850248-65-6 CAPLUS
CN Glycine, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 850248-64-5
CMF C24 H19 F3 N6 O3



CH 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850248-67-8 CAPLUS

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Butanamide, 4-amino-N-[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 850248-66-7
 CMF C26 H24 F3 N7 O2




CH 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 850248-68-9 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(4-amino-3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-69-0 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 850248-70-3 CAPLUS


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850248-75-8 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-76-9 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-77-0 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-[2-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-78-1 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-ethylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-71-4 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-72-5 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2-ethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-73-6 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2-fluoro-5-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-74-7 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2,3-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850248-79-2 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 850248-81-6 CAPLUS
 CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 850248-82-7 CAPLUS
 CN Phenol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850248-83-8 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(3-amino-4-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-84-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-85-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl


RN 850248-86-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-hydroxy-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850248-87-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-amino-4-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850248-92-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-amino-3-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)





RN 850248-93-0 CAPLUS
CN Carbamic acid, [4-[2-amino-6-[[4-[[2-(cyano-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 850248-95-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-amino-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 850248-94-1
CMF C23 H19 N7 O2




RN 850248-88-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-amino-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850248-89-4 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 850248-90-7 CAPLUS
CN Benzenemethanol, 2-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850248-91-8 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 850248-96-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-amino-3-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-98-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-chlorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-00-2 CAPLUS
CN Benzonitrile, 2-amino-5-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-01-3 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl ester (9CI) (CA INDEX NAME)




RN 850249-02-4 CAPLUS
CN Sulfamide, [4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-03-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[1,1'-biphenyl]-4-yl-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-05-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,4-dimethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-06-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-13-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-14-8 CAPLUS
CN Benzonitrile, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-15-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(dimethylamino)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-16-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-08-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-09-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-10-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-12-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-17-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[2-methoxy-5-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-18-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[2-methylphenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-20-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,4-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-21-7 CAPLUS
CN Benzenemethanol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-22-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-23-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(4-ethylthio)phenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-24-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(3-amino-4-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-25-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(1-methylethyl)phenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-32-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(3-(trifluoromethoxy)phenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-33-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(4-(trifluoromethoxy)phenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-35-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(3,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-38-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-26-2 CAPLUS
CN Benzeneacetonitrile, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-27-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(4-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-28-4 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-31-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[(2,5-dimethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-40-0 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-fluoro[1,1'-biphenyl]-4-yl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-42-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-(phenylmethoxy)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-44-4 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3,4-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-45-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-47-7 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-48-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-hydroxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-54-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-57-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-(methylthio)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-70-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-73-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-75-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-77-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-59-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-(dimethylamino)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-61-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-63-7 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-64-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-(cyanomethyl)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-78-4 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-79-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-(trifluoromethyl)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-80-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-methoxy-5-(1-methylethyl)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-81-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-82-0 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2,4-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-83-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-84-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-85-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-92-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)





RN 850249-93-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-95-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-96-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-fluoro[1,1'-biphenyl]-4-yl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-87-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-amino-4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-88-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3,4-dichlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-89-7 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-91-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)


RN 850249-97-7 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-ethylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-98-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-methoxy-5-(1-methylethyl)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-99-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-00-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2,4-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-01-0 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-02-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)





RN 850250-03-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-04-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-06-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-12-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-13-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-14-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-15-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)


RN 850250-07-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-08-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-09-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-10-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-11-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-18-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-40-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-41-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-42-9 CAPLUS
CN Phenol, 3-[[2-amino-6-[[4-[[1-methylethyl]phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-43-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 850250-44-1 CAPLUS
CN Acetamide, N-[4-[2-amino-6-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-45-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 850250-46-3 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850250-52-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(4-ethylphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-53-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(dimethylamino)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-54-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3,4-dimethoxyphenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-55-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-amino-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 850250-47-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(3-methoxyphenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-49-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[4-(4-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-50-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850250-51-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(3-fluorophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-57-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[2-(4-aminophenyl)-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-58-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(1-methylethoxy)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-59-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(1-methylethoxy)phenyl]-N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850250-60-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 850250-61-2 CAPLUS
CN Sulfamic acid, 4-([2-amino-6-([4-([2-chloro-4-pyridinyl]oxy)phenyl]amino)-4-pyrimidinyl]phenyl) ester (9CI) (CA INDEX NAME)



RN 850250-81-6 CAPLUS
CN Acetamide, 2-([4-([2-amino-6-([4-([2-(trifluoromethyl)-4-pyridinyl]oxy)phenyl]amino)-4-pyrimidinyl]phenyl]amino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850250-80-5
CMF C24 H20 F3 N7 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2





RN 850252-00-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-([4-([2-amino-6-phenyl-4-pyrimidinyl]amino)-3-fluorophenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-([2-(trifluoromethyl)-4-pyridinyl]oxy)phenyl]- (9CI) (CA INDEX NAME)




RN 871240-10-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-([2-(trifluoromethyl)-4-pyridinyl]oxy)phenyl]- (9CI) (CA INDEX NAME)




● HCl


RN 850252-01-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[4-([2-(trifluoromethyl)-4-pyridinyl]oxy)phenyl]- (9CI) (CA INDEX NAME)



RN 871240-05-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,6-dimethylphenyl)-N4-[4-([2-(trifluoromethyl)-4-pyridinyl]oxy)phenyl]- (9CI) (CA INDEX NAME)



RN 871240-08-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-([2-(trifluoromethyl)-4-pyridinyl]oxy)phenyl]- (9CI) (CA INDEX NAME)



IT 850250-76-9P 871240-10-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino-substituted pyrimidines as antitumor agents)
RN 850250-76-9 CAPLUS

L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1130634 CAPLUS
DOCUMENT NUMBER: 143:405919
TITLE: Preparation of heteroaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors
INVENTOR(S): Schirok, Hartmut; Radtke, Martin; Mittendorf, Joachim; Kört, Raimund; Stasch, Johannes-Peter; Gnoth, Mark Jean; Muentert, Klaus; Lang, Dieter; Figueroa Perez, Santiago; Thutewohl, Michael; Bennabi, Samir; Ehmeke, Heimo
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097790	A1	20051020	WO 2005-EP3294	20050330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GQ, ML, MR, NE, SN, TD, TG				
DE 102004017438	A1	20051103	DE 2004-102004017438	20040408
CA 2563212	A1	20051020	CA 2005-2563212	20050330
EP 1751153	A1	20070214	EP 2005-740054	20050330
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			DE 2004-102004017438A	20040408
OTHER SOURCE(S):		MARPAT 143:405919	WO 2005-EP3294	W 20050330
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = Cl, Br, CN, etc.; R2 = H or F; R3 = H, Cl, CF3, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as Rho kinase inhibitors. Thus, e.g., I was prepared by coupling of 3,5-difluoro-4-([3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy)aniline (preparation given) with 4,6-dichloropyrimidin-2-amine. The inhibitory activity of I towards Rho kinase was evaluated using scintillation assay and it was revealed that selected compds. of the invention possessed IC50 values in the range of 2 up to 7 nM. I as Rho kinase inhibitors should prove useful in the treatment of cardiovascular disease and erectile dysfunction. Pharmaceutical compds. comprising I are disclosed.

IT 867017-68-3P 867017-69-4P 867017-70-7P
867017-71-8P 867017-72-9P 867017-73-0P
867017-74-1P 867017-75-2P 867017-76-3P
867017-77-4P 867017-78-5P 867017-79-6P

L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


867017-80-9P 867017-81-0P 867017-82-1P
867017-83-2P 867017-84-3P 867017-85-4P
867017-86-5P 867017-87-6P 867017-88-7P
867017-89-8P 867017-90-1P 867017-91-2P
867017-92-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of heteroaryloxy-substituted phenylamino pyrimidines as Rho
kinase inhibitors)


RN 867017-68-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3,5-difluoro-4-[(3-methyl-1H-
pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 867017-69-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-
b]pyridin-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 867017-70-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-
b]pyridin-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 867017-73-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-
4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 867017-74-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-
4-yl)oxy]phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

b]pyridin-4-yl)oxy]phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-71-8 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-
3,5-difluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-72-9 CAPLUS


CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-
b]pyridin-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 867017-75-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-
4-yl)oxy]-3-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 867017-76-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-
3-fluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 867017-77-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl- (9CI) (CA INDEX NAME)




RN 867017-78-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 867017-79-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[(3-ethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl- (9CI) (CA INDEX NAME)




RN 867017-80-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(3-ethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 867017-81-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-ethanol, 4-[(2-amino-6-chloro-4-pyrimidinyl)amino]-2-fluorophenoxy- (9CI) (CA INDEX NAME)




RN 867017-82-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-ethanol, 4-[(2-amino-6-(trifluoromethyl)-4-pyrimidinyl)amino]-2-fluorophenoxy- (9CI) (CA INDEX NAME)




RN 867017-83-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-ethanol, 4-[(2-amino-4-pyrimidinyl)amino]-2-fluorophenoxy- (9CI) (CA INDEX NAME)




RN 867017-84-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(3-methoxyethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 867017-85-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile, 4-[(2-amino-6-(trifluoromethyl)-4-pyrimidinyl)amino]-2-fluorophenoxy- (9CI) (CA INDEX NAME)




RN 867017-86-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile, 4-[(2-amino-6-chloro-4-pyrimidinyl)amino]-2-fluorophenoxy- (9CI) (CA INDEX NAME)




RN 867017-87-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile, 4-[(2-amino-4-pyrimidinyl)amino]-2-fluorophenoxy- (9CI) (CA INDEX NAME)




RN 867017-88-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile, 4-[(2-amino-4-pyrimidinyl)amino]-2,6-difluorophenoxy- (9CI) (CA INDEX NAME)




RN 867017-89-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(3-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 867017-90-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-91-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 867017-92-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[(3-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:902740 CAPLUS
 DOCUMENT NUMBER: 143:263095
 TITLE: Selective high-affinity polydentate ligands and methods of making such
 INVENTOR(S): Denardo, Sally; Denardo, Gerald; Rodney, Balhorn
 PATENT ASSIGNEE(S): The Regents of the University of California, USA
 SOURCE: PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077065	A2	20050825	WO 2005-US4134	20050208
WO 2005077065	A3	20051222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2006084115 A1 20060420 US 2005-55181 20050209
 PRIORITY APPL. INFO.: US 2004-543444 P 20040208
 AB This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region of the target mol. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target mol. with high selectivity and avidity.
 IT 339016-03-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (selective high-affinity polydentate ligands and methods of making such)
 RN 339016-03-4 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxypheyl)- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 2005:460527 CAPLUS
 DOCUMENT NUMBER: 143:153526
 TITLE: Antileishmanial agents part-IV: synthesis and antileishmanial activity of novel terpenyl pyrimidines
 AUTHOR(S): Chandra, Naveen; Ramesh; Ashutosh; Goyal, Neena; Suryawanshi, S. N.; Gupta, Suman
 CORPORATE SOURCE: Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, 226001, India
 SOURCE: European Journal of Medicinal Chemistry (2005), 40(6), 552-556
 CODEN: EJMCAS; ISSN: 0223-5234
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:153526
 GI



AB Some novel N- and O-substituted terpenyl pyrimidine derivs., I [R = NHC6H4OMe-4, NHC6H4Cl-4, piperazino, 4-Ph-piperazino, NHPh, N(CH2)5, morpholino, OMe, OEt, OBu], have been synthesized and screened for in vitro antileishmanial activity profile in promastigote model. Some of the compds. exhibited 100% inhibition at 10 µg ml⁻¹ concentration
 IT 860021-28-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antileishmanial activity of terpenyl pyrimidine derivs.)
 RN 860021-28-9 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(4-methoxyphenyl)-6-[(1E)-2-(2,6,6-trimethyl-2-cyclohexen-1-yl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:346995 CAPLUS
 DOCUMENT NUMBER: 142:411371
 TITLE: Preparation of pyrimidine derivatives as antitumor agents
 INVENTOR(S): Dixon, Julie A.; Nagarathnam, Dhanapalan; Zhang, Lei; Wang, Chunguang; Yi, Lin; Chen, Yuanwei; Chen, Jiangqiang; Bear, Brian; Brands, Michael; Hillisch, Alexander; Bierer, Donald; Wang, Ming; Fu, Wenliang; Hentemann, Martin F.; Bullion, Ann-Marie
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 276 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035507	A2	20050421	WO 2004-US33430	20041008
WO 2005035507	A3	20060831		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


CA 2542031 A1 20050421 CA 2004-2542031 20041008
 EP 1689722 A2 20060816 EP 2004-809919 20041008
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 JP 2007508321 T 20070405 JP 2006-534438 20041008
 US 2005277640 A1 20051215 US 2005-78681 20050310
 US 2007117817 A1 20070524 US 2006-573227 20060324
 PRIORITY APPL. INFO.: US 2003-510804 P 20031010
 WO 2004-US33430 W 20041008

OTHER SOURCE(S): MARPAT 142:411371
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl, cyclopropyl; R2 = alkyl, cyclopropyl, O-alkyl, etc.; R3 = H, halo; M = CH, N; L = carbonyl, O, (un)substituted-alkylenyl, etc.; J and Y independently = (un)substituted-aryl, -heteroaryl; A = halo, CF3, CN, etc.; m = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as useful antitumor agents. Thus, e.g., I was prepared by etherification of 4-chloro-picoline with 4-aminophenol followed by amination of 4-chloro-6-phenylpyrimidin-2-amine (preparation given). The cytotoxic activity of I towards HCT116 cells was evaluated and selected compds. of the invention displayed IC50 values of less than or equal to 500 nM. I should


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
prove useful in the treatment of hyperproliferative disorders.
IT 850247-06-2P 850247-12-0P 850247-26-6P
850247-28-8P 850247-38-0P 850247-41-5P
850248-80-5P
RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. as antitumor agents)
RN 850247-06-2 CAPLUS
CN 2-Pyridinecarboxitrile, 4-[4-[(2-amino-6-phenyl-4-
pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-12-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-
pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850247-26-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[(2-(trifluoromethyl)-4-
pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850247-28-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-(aminomethyl)-4-pyridinyl)oxy]phenyl]-6-
phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850247-38-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-chloro-4-pyridinyl)oxy]phenyl]-6-phenyl-
(9CI) (CA INDEX NAME)



RN 850247-41-5 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[(2-(trifluoromethyl)-4-
pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850248-80-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[(2-(trifluoromethyl)-4-
pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



IT 850246-99-0P 850247-00-6P 850247-03-9P
850247-04-0P 850247-05-1P 850247-09-5P
850247-10-8P 850247-11-9P 850247-14-2P
850247-15-3P 850247-17-5P 850247-21-1P
850247-27-7P 850247-30-2P 850247-31-3P
850247-32-4P 850247-33-5P 850247-34-6P
850247-35-7P 850247-36-8P 850247-37-9P


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

850247-39-1P 850247-40-4P 850247-42-6P
850247-43-7P 850247-44-8P 850247-46-0P
850247-48-2P 850247-50-6P 850247-51-7P
850247-52-8P 850247-54-0P 850247-55-1P
850247-56-2P 850247-57-3P 850247-58-4P
850247-59-5P 850247-60-8P 850247-61-9P
850247-63-1P 850247-65-3P 850247-68-6P
850247-70-0P 850247-71-1P 850247-73-3P
850247-75-5P 850247-76-6P 850247-77-7P
850247-78-8P 850247-80-2P 850247-86-8P
850247-88-0P 850247-91-5P 850247-94-8P
850247-97-1P 850248-00-9P 850248-03-2P
850248-04-3P 850248-05-4P 850248-07-6P
850248-08-7P 850248-09-8P 850248-10-1P
850248-11-2P 850248-12-3P 850248-13-4P
850248-14-5P 850248-15-6P 850248-16-7P
850248-17-8P 850248-18-9P 850248-20-3P
850248-21-4P 850248-22-5P 850248-23-6P
850248-24-7P 850248-41-8P 850248-43-0P
850248-45-2P 850248-46-3P 850248-47-4P
850248-48-5P 850248-49-6P 850248-50-9P
850248-51-0P 850248-52-1P 850248-53-2P
850248-54-3P 850248-55-4P 850248-56-5P
850248-57-6P 850248-58-7P 850248-59-8P
850248-61-2P 850248-62-3P 850248-63-4P
850248-65-6P 850248-67-8P 850248-68-9P
850248-69-0P 850248-70-3P 850248-71-4P
850248-72-5P 850248-73-6P 850248-74-7P
850248-75-8P 850248-76-9P 850248-77-0P
850248-78-1P 850248-79-2P 850248-81-6P
850248-82-7P 850248-83-8P 850248-84-9P
850248-85-0P 850248-86-1P 850248-87-2P
850248-88-3P 850248-89-4P 850248-90-7P
850248-91-8P 850248-92-9P 850248-93-0P
850248-95-2P 850248-96-3P 850248-98-5P
850249-00-2P 850249-01-3P 850249-02-4P
850249-03-5P 850249-05-7P 850249-06-8P
850249-08-0P 850249-09-1P 850249-10-2P
850249-12-6P 850249-13-7P 850249-14-8P
850249-15-9P 850249-16-0P 850249-17-1P
850249-18-2P 850249-20-6P 850249-21-7P
850249-22-8P 850249-23-9P 850249-24-0P
850249-25-1P 850249-26-2P 850249-27-3P
850249-28-4P 850249-31-9P 850249-32-0P
850249-33-1P 850249-35-3P 850249-38-6P
850249-40-0P 850249-42-2P 850249-44-6P
850249-45-5P 850249-47-7P 850249-48-8P
850249-54-6P 850249-57-9P 850249-59-1P
850249-61-5P 850249-63-7P 850249-64-8P
850249-70-6P 850249-73-9P 850249-75-1P
850249-77-3P 850249-78-4P 850249-79-5P
850249-80-8P 850249-81-9P 850249-82-0P
850249-83-1P 850249-84-2P 850249-85-3P
850249-87-5P 850249-88-6P 850249-89-7P
850249-91-1P 850249-92-2P 850249-93-3P
850249-95-5P 850249-96-6P 850249-97-7P
850249-98-8P 850249-99-9P 850250-00-9P
850250-01-0P 850250-02-1P 850250-03-2P
850250-04-3P 850250-06-5P 850250-07-6P
850250-08-7P 850250-09-8P 850250-10-1P


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(prepn. of pyrimidine derivs. as antitumor agents)


RN 850246-99-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-ethyl-4-pyridinyl)oxy]phenyl]-6-phenyl-
(9CI) (CA INDEX NAME)




RN 850247-00-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-phenyl-
(9CI) (CA INDEX NAME)




RN 850247-03-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(3,5-difluoro-4-pyridinyl)oxy]phenyl]-6-
phenyl- (9CI) (CA INDEX NAME)




RN 850247-04-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(4-nitrophenyl)oxy]phenyl]-6-phenyl- (9CI) (CA




RN 850247-05-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-09-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-chlorophenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-10-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4-methoxyphenoxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-11-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 850247-17-5 CAPLUS
CN Piperazine, 1-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-4-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1
CRN 850247-16-4
CMF C27 H27 N7 O2




CH 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850247-21-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-(2-(4-morpholinyl)ethoxy]-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-27-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[1-oxido-2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-14-2 CAPLUS
CN Morpholine, 4-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)



CH 1
CRN 850247-13-1
CMF C26 H24 N6 O3



CH 2
CRN 76-05-1
CMF C2 H F3 O2




RN 850247-15-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 850247-30-2 CAPLUS
CN Methanesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1
CRN 850247-29-9
CMF C23 H22 N6 O3 S




CH 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850247-31-3 CAPLUS
CN Benzamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 850247-32-4 CAPLUS
CN Urea, N'-[[4-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl)methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)





RN 850247-33-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-(methoxymethyl)-1-pyrrolidinyl]-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 850247-34-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[1-methylethyl]amino]methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-40-4 CAPLUS
CN Propanamide, 2-amino-N-[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850247-42-6 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)




RN 850247-43-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-amino-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI), (CA INDEX NAME)


RN 850247-35-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 850247-36-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[[4-[[2-(1H-tetrazol-5-yl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-37-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[4,5-dihydro-1H-imidazol-2-yl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-39-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[2-(methoxymethyl)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850247-44-8 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(chloro-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850247-46-0 CAPLUS
CN 3-Buten-1-ol, 4-[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl-, (3E)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-45-9
CMP C25 H23 N5 O2

Double bond geometry as shown.



CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 850247-48-2 CAPLUS
CN 2-Pyridinemethanol, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-47-1
CMF C22 H19 N5 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850247-50-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[[4-(5-pyrimidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850247-51-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-(4-aminophenoxy)phenyl]-6-phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(9CI) (CA INDEX NAME)




RN 850247-56-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[(2-chloro-4-pyridinyl)oxy]-2-fluorophenyl]-6-phenyl]- (9CI) (CA INDEX NAME)




RN 850247-57-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[2-fluoro-4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl]- (9CI) (CA INDEX NAME)




RN 850247-58-4 CAPLUS
CN Benzonitrile, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-59-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850247-52-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[(4-bromo-2-pyridinyl)oxy]phenyl]-6-phenyl]- (9CI) (CA INDEX NAME)



RN 850247-54-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[(2-fluoro-4-pyridinyl)oxy]phenyl]-6-phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-53-9
CMF C21 H16 F N5 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850247-55-1 CAPLUS
CN 2(1H)-Pyridinone, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850247-60-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-methyl]- (9CI) (CA INDEX NAME)




RN 850247-61-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(2-amino-6-(4-fluorophenyl)-4-pyrimidinyl)amino]phenoxy]-N-methyl]- (9CI) (CA INDEX NAME)




RN 850247-63-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(2-amino-6-(4-fluorophenyl)-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-65-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[(2-amino-6-(4-fluorophenyl)-4-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850247-68-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 850247-70-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-1-azabicyclo[2.2.2]oct-3-yl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 850247-69-7
CMF C29 H29 N7 O2



CH 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850247-75-5 CAPLUS
CN 3-Pyrrolidinol, 1-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-, (3R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 850247-74-4
CMF C26 H24 N6 O3

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2



RN 850247-76-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-butoxy-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-71-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-N-(2,3-dihydroxypropyl)- (9CI) (CA INDEX NAME)




RN 850247-73-3 CAPLUS
CN Pyrrolidine, 1-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]carbonyl]-2-(methoxymethyl)-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 850247-72-2
CMF C28 H28 N6 O3

Absolute stereochemistry.




CH 2


CRN 76-05-1
CMF C2 H F3 O2



RN 850247-77-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-(2-methoxyethoxy)-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850247-78-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-(2-(dimethylamino)ethoxy)-4-pyridinyl)oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850247-80-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-ethoxy-4-pyridinyl)oxy]phenyl]-6-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 850247-79-9
CMF C23 H21 N5 O2



CH 2


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CRN 76-05-1
 CMF C2 H F3 O2



RN 850247-86-8 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-28-8
 CMF C22 H20 N6 O



CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 850247-88-0 CAPLUS
 CN 1H-Imidazole-4-sulfonamide, N-[[4-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-87-9
 CMF C26 H24 N8 O3 S


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850247-94-8 CAPLUS
 CN 2-Propanesulfonamide, N-[[4-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-93-7
 CMF C25 H26 N6 O3 S



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 850247-97-1 CAPLUS
 CN Benzenesulfonamide, N-[[4-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-96-0
 CMF C28 H24 N6 O3 S

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 850247-91-5 CAPLUS
 CN Ethanesulfonamide, N-[[4-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 850247-90-4
 CMF C24 H24 N6 O3 S



CM 2

CRN 76-05-1
 CMF C2 H F3 O2

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 850248-00-9 CAPLUS
 CN Benzenesulfonamide, N-[[4-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]methyl]-4-methoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850247-99-3
 CMF C29 H26 N6 O4 S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 850248-03-2 CAPLUS
CN Benzenesulfonamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-4-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-02-1
CMF C28 H23 F N6 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 02




RN 850248-04-3 CAPLUS
CN Urea, N'-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 850248-05-4 CAPLUS


RN 850248-09-8 CAPLUS
CN Urea, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-N',N'-diethyl-N-methyl- (9CI) (CA INDEX NAME)




RN 850248-10-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl)methyl]-N-methyl- (9CI) (CA INDEX




RN 850248-11-2. CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-(4-morpholinyl)-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-12-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-{4-[(4-(1-piperidinyl)-2-pyridinyl)oxy]phenyl}- (9CI) (CA INDEX NAME)




RN 850248-13-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-(4-methyl-1-piperazinyl)-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-07-6 CAPLUS
CN Urea, [[4-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 850248-06-5
CMF C23 H21 N7 O2




CM 2


CRN 76-05-1
CMF C2 H F3 Q2




RN 850248-08-7 CAPLUS
CN Urea, [[4-(4-((2-amino-6-phenyl-4-pyrimidinyl)amino)phenoxy)-2-pyridinyl]methyl]trimethyl- (9CI) (CA INDEX NAME)

CN1CCN(CC1)c2ccc(Oc3ccc(Nc4nc(N)nc(C5=CC=CC=C5)c4)cc3)cn2


RN 850248-14-5 CAPLUS
 CN Ethanol, 2,2'-[(2-[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-4-pyridinyl)imino]bis- (9CI) (CA INDEX NAME)



RN 850248-15-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[4-(bis(2-methoxyethyl)amino)-2-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-16-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[[2-[[1-ethylpropyl]amino]methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-17-8 CAPLUS


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(cyclohexylamino)methyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-18-9 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(3,4-dichlorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-20-3 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-(2-chloro-4-pyridinyl)oxy]phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 850248-21-4 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-(2-chloro-4-pyridinyl)oxy]phenyl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 850248-22-5 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[[2-(2-chloro-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 850248-45-2 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-[(phenylmethyl)amino]-4-pyridinyl]oxy]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
 CRN 850248-44-1
 CMF C28 H24 N6 O




CH 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 850248-46-3 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850248-23-6 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-(2-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-24-7 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(2-chloro-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-41-8 CAPLUS
 CN Ethanol, 2,2'-[[4-[[4-[[2-(2-amino-6-phenyl-4-pyrimidinyl)amino]phenoxy]-2-pyridinyl]imino]bis- (9CI) (CA INDEX NAME)




RN 850248-43-0 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[4-[[2-[(1-(phenylmethyl)hydrazino)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850248-47-4 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4-morpholinyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-48-5 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4-methyl-1-piperazinyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-49-6 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-(4-(2-methoxyethyl)-1-piperazinyl)-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 850248-50-9 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-[(2-methoxyethyl)methylamino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)







RN 850248-51-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[2-(dimethylamino)ethyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-52-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-N4-[[4-[[2-(1-piperidinyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-53-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-bis(2-methoxyethyl)amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 850248-54-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[3-(diethylamino)propyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 850248-58-7 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850248-59-8 CAPLUS
CN 3-Pyrrolidinol, 1-[[4-[[2-amino-6-phenyl-4-pyrimidinyl]amino]phenoxy]-2-pyridinyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 850248-61-2 CAPLUS
CN Butanoic acid, 4-[[4-[[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 850248-62-3 CAPLUS
CN Glycine, N-[[1,1-dimethylethoxy]carbonyl]-, 4-[[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl ester (9CI) (CA INDEX NAME)



RN 850248-55-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)





RN 850248-56-5 CAPLUS
CN Phenol, 4-[[2-amino-6-[[4-[[2-(4-morpholinyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 850248-57-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-[[2-[[3S]-3-(dimethylamino)-1-pyrrolidinyl]-4-pyridinyl]oxy]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850248-63-4 CAPLUS
CN Glycine, 4-[[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 850248-65-6 CAPLUS
CN Glycine, 4-[[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850248-64-5
CMF C24 H19 F3 N6 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850248-67-8 CAPLUS

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Butanamide, 4-amino-N-[4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 850248-66-7
 CMF C26 H24 F3 N7 O2




CH 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 850248-68-9 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(4-amino-3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-69-0 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 850248-70-3 CAPLUS


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850248-75-8 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-76-9 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethoxy)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-77-0 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-[2-(1-methylethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-78-1 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[4-[[2-(aminomethyl)-4-pyridinyl]oxy]phenyl]-6-(2-ethylphenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2,4-Pyrimidinediamine, 6-[2-(trifluoromethyl)phenyl]-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-71-4 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2-ethylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-72-5 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2-ethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-73-6 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2-fluoro-5-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-74-7 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2,3-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 850248-79-2 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 850248-81-6 CAPLUS
 CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 850248-82-7 CAPLUS
 CN Phenol, 3-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850248-83-8 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(3-amino-4-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 850248-84-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-85-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-aminophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 850248-86-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-hydroxy-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850248-87-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3-amino-4-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850248-92-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-amino-3-fluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)





RN 850248-93-0 CAPLUS
CN Carbamic acid, [4-[2-amino-6-[[4-[[2-(cyano-4-pyridinyl)oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 850248-95-2 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-amino-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 850248-94-1
CHF C23 H19 N7 O2




RN 850248-88-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-amino-3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850248-89-4 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 850248-90-7 CAPLUS
CN Benzenemethanol, 2-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850248-91-8 CAPLUS
CN Phenol, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 850248-96-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-amino-3-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850248-98-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-chlorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-00-2 CAPLUS
CN Benzonitrile, 2-amino-5-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-01-3 CAPLUS
CN Sulfamic acid, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]-2-methoxyphenyl ester (9CI) (CA INDEX NAME)




RN 850249-02-4 CAPLUS
CN Sulfamide, [4-[[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-03-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[1,1'-biphenyl]-4-yl-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-05-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,4-dimethoxyphenyl)-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-06-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-methoxyphenyl)-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-13-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[3-(trifluoromethyl)phenyl]-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-14-8 CAPLUS
CN Benzonitrile, 3-[[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-15-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[4-(dimethylamino)phenyl]-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-16-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-ethylphenyl)-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-08-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-09-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-fluorophenyl)-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-10-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-aminophenyl)-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-12-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-fluorophenyl)-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-17-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[2-methoxy-5-(1-methylethyl)phenyl]-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-18-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-20-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,4-difluorophenyl)-N4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-21-7 CAPLUS
CN Benzenemethanol, 3-[[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-22-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-23-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-(ethylthio)phenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-24-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-amino-4-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-25-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-(1-methylethyl)phenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-32-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-(trifluoromethoxy)phenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-33-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-(trifluoromethoxy)phenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-35-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3,5-difluorophenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-38-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-26-2 CAPLUS
CN Benzeneacetonitrile, 4-[2-amino-6-[[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850249-27-3 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(4-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-28-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(3-methylphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-31-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2,5-dimethoxyphenyl)-N4-[4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850249-40-0 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(2-fluoro[1,1'-biphenyl]-4-yl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-42-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-(phenylmethoxy)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-44-4 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(3,4-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-45-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[4-[[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-47-7 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-48-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-hydroxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-54-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-57-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-(methylthio)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-70-6 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-73-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-75-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-77-3 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-59-1 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-(dimethylamino)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-61-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2,5-dimethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-63-7 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-64-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(4-(cyanomethyl)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-78-4 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-79-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(3-(trifluoromethyl)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-80-8 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-methoxy-5-(1-methylethyl)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-81-9 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-82-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2,4-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-83-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-84-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-85-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-92-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)





RN 850249-93-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-95-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-96-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2-fluoro[1,1'-biphenyl]-4-yl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-87-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-amino-4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850249-88-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3,4-dichlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-89-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-aminophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-91-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)


RN 850249-97-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-ethylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-98-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2-methoxy-5-(1-methylethyl)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850249-99-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-00-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(2,4-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-01-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[2-amino-6-(3-(hydroxymethyl)phenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-02-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-[(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)





RN 850250-03-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-(4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-04-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-(3-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-06-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-[3-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-12-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-(3,5-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 850250-13-4 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-14-5 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-15-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-(3,5-difluorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)


RN 850250-07-6 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-(3-amino-4-methylphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-08-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-(3,4-dichlorophenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)





RN 850250-09-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-(3-ethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-10-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-11-2 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[[2-amino-6-[2-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 850250-18-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[4-[[2-methyl-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-40-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[4-[[2-methyl-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-41-8 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[3-[[dimethylamino]phenyl]-N4-[[4-[[2-methyl-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-42-9 CAPLUS
CN Phenol, 3-[[2-amino-6-[[4-[[2-methyl-4-pyridinyl]oxy]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850250-43-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(4-(trifluoromethoxy)phenyl)]- (9CI) (CA INDEX NAME)




RN 850250-44-1 CAPLUS
CN Acetamide, N-[4-[2-amino-6-[(4-[(2-methyl-4-pyridinyl)oxy]phenyl)amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 850250-45-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 850250-46-3 CAPLUS
CN Phenol, 4-[2-amino-6-[(4-[(2-methyl-4-pyridinyl)oxy]phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850250-52-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(4-ethylphenyl)]- (9CI) (CA INDEX NAME)




RN 850250-53-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(4-(dimethylamino)phenyl)]- (9CI) (CA INDEX NAME)




RN 850250-54-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(3,4-dimethoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 850250-55-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(3-aminophenyl)]- (9CI) (CA INDEX NAME)




RN 850250-47-4 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(3-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 850250-49-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(4-aminophenyl)]- (9CI) (CA INDEX NAME)




RN 850250-50-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850250-51-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(3-fluorophenyl)]- (9CI) (CA INDEX NAME)




RN 850250-57-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(2-aminophenyl)]- (9CI) (CA INDEX NAME)




RN 850250-58-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(3-amino-4-methylphenyl)]- (9CI) (CA INDEX NAME)




RN 850250-59-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[(3-(1-methylethoxy)phenyl)]- (9CI) (CA INDEX NAME)



RN 850250-60-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[(2-methyl-4-pyridinyl)oxy]phenyl]-6-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 850250-61-2 CAPLUS
CN Sulfamic acid, 4-[[2-amino-6-[[4-[(2-chloro-4-pyridinyl)oxy]phenyl]amino]-4-pyridinyl]phenyl ester (9CI) (CA INDEX NAME)




RN 850250-81-6 CAPLUS
CN Acetamide, 2-[[4-[[2-amino-6-[[4-[(2-trifluoromethyl)-4-pyridinyl]oxy]phenyl]amino]-4-pyridinyl]phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 850250-80-5

CMF C24 H20 F3 N7 O2



CH 2

CRN 76-05-1



CMF C2 H F3 O2




RN 850252-00-5 CAPLUS
CN 2-Pyridinecarbonitrile, 4-[[4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]-3-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2005:120898 CAPLUS
DOCUMENT NUMBER: 142:219297
TITLE: Preparation of pyrimidine analogs as 5-HT2b receptor antagonists
INVENTOR(S): Borman, Richard Anthony; Coleman, Robert Alexander; Clark, Kenneth Lyle; Oxford, Alexander William; Hynd, George; Archer, Janet Ann; Aley, Amanda; Harris, Neil Victor
PATENT ASSIGNEE(S): Pharmagene Laboratories Limited, UK
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012263	A1	20050210	WO 2004-GB3184	20040723
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, BO, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2532505	A1	20050210	CA 2004-2532505	20040723
EP 1648876	A1	20060426	EP 2004-743517	20040723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2006528617	T	20061221	JP 2006-520897	20040723
PRIORITY APPLN. INFO.:			GB 2003-17346	A 20030724
			US 2003-490286P	P 20030728
			WO 2004-GB3184	W 20040723
OTHER SOURCE(S):			CASREACT 142:219297; MARPAT 142:219297	
GI				




AB Title compds. represented by the formula I [wherein X = O or NH; R1 = (un)substituted aryl; R2, R3 = independently, (un)substituted (cyclo)alkyl, cycloalkylalkyl, phenylalkyl; R4, R5 = independently, H, (un)substituted (phenyl)alkyl, sulfonylalkyl, carbonylalkyl, alkylamino or R4R5 = (un)substituted heterocyclic group; and pharmaceutically acceptable




● HCl

RN 850252-01-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(2-methylphenyl)-N4-[[4-[(2-methyl-4-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




IT 850250-76-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. as antitumor agents)

RN 850250-76-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[[4-[(2-trifluoromethyl)-4-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




salts or solvates thereof], and 3 addnl. Markush structures, were prepd. as 5-HT2b receptor agonists. For example, reaction of 2-amino-4-chloro-6-methylpyrimidine with aniline in the microwave cavity gave II. I were tested for binding activity of 5-HT2A, 5-HT2B and 5-HT2C. Thus, I and their pharmaceutical compns. are useful for the treatment of a condition alleviated by antagonism of a 5-HT2B receptor, such as digestive tract disease (no data).
IT 842154-19-2P 842154-21-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinyl, imidazolyl, oxazolyl and triazolyl amine derivs. as 5-HT2b receptor antagonists)
RN 842154-19-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 842154-21-6 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-(4-phenoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:957162 CAPLUS
 DOCUMENT NUMBER: 141:350185
 TITLE: Preparation of pyrimidine derivatives with lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitory activity
 INVENTOR(S): Bhatt, Rama; Gong, Baoqing; Hong, Feng; Jenkins, Scott A.; Klein, J. Peter; Kohn, Cory T.; Tulinsky, John
 PATENT ASSIGNEE(S): Cell Therapeutics, Inc.; USA
 SOURCE: U.S. Pat. Appl. Publ., 80 pp., which CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004204386	A1	20041014	US 2003-671070	20030924
PRIORITY APPLN. INFO.:			US 2002-419694P	P 20021017
			US 2003-460776P	P 20030404

OTHER SOURCE(S): MARPAT 141:350185
 GI




I




II

AB The title compds. I [X, Y, Z = N, CH, or CR with the proviso that two of X, Y and Z are N; R = alkyl, alkoxy, Cl, Br, (substituted)amino; Q = NR', R''-(CH2)n, (CH2)n-NR', O, O-(CH2)n, S, S-(CH2)n, or (CH2)n-S; n = 1-10; R' = H or alkyl; R'' = H, OH, alkyl, alkoxy, Cl, F, Br, etc.; R2, R7 = H, OH, alkyl, alkoxy, Cl, F, Br, I, etc.; R3 = H, alkyl, alkoxy, Cl, CCl3 (substituted)amino; R4, R5, R6 = H, OH, alkyl, alkenyl, alkynyl, alkoxy, etc. or R4, R5 or R5, R6 are taken together with benzene ring to


L4 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 774606-32-5 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774606-50-7 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774606-79-0 CAPLUS
 CN Ethanol, 2-[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 form a heterocycle are prepd. as lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitors for the treatment of diseases related to cell proliferation, such as cancer. For example, reaction of 6-chloro-N4-(4-methylphenyl)-pyrimidine-2,4-diamine (prepn. given) with 5-chloro-2-methoxy-Ph boronic acid yielded compd. II. The latter exhibits an IC50 = 0.12 μ M in the LPAAT- β assay.
 IT 774606-11-0P 774606-12-1P 774606-21-2P 774606-22-3P 774606-32-5P 774606-50-7P 774606-79-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 [preparation of pyrimidine derivs. with lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitory activity]
 RN 774606-11-0 CAPLUS
 CN Phenol, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 774606-12-1 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 774606-21-2 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774606-22-3 CAPLUS
 CN Phenol, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:390240 CAPLUS
 DOCUMENT NUMBER: 140:406815
 TITLE: Preparation of phenylaminopyrimidines as Rho-Kinase II (ROKs) inhibitors for the treatment of cardiovascular diseases.
 INVENTOR(S): Feurer, Achim; Bennabi, Samir; Heckroth, Heike; Schirok, Hartmut; Mittendorf, Joachim; Kast, Raimund; Stasch, Johannes-peter; Gnoth, Mark Jean; Munter, Klaus; Lang, Dieter; Figueroa, Perez Santiago; Ehmke, Heimo
 PATENT ASSIGNEE(S): Bayer Healthcare Ag, Germany; et al.
 SOURCE: PCT Int. Appl., 203 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039796	A1	20040513	WO 2003-EP11452	20031016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10332232	A1	20040513	DE 2003-10332232	20030716
CA 2503646	A1	20040513	CA 2003-2503646	20031016
AU 2003278088	A1	20040525	AU 2003-278088	20031016
EP 1562935	A1	20050817	EP 2003-769398	20031016
EP 1562935	B1	20060906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006506458	T	20060223	JP 2005-501803	20031016
US 2006241127	A1	20061026	US 2005-531889	20050419
PRIORITY APPLN. INFO.:			DE 2002-10250113	A 20021028
			DE 2003-10332232	A 20030716
			WO 2003-EP11452	W 20031016

OTHER SOURCE(S): MARPAT 140:406815
 GI




AB Title compds. I [A = (un)substituted indazole, dihydrobenzofuran, indoline, etc.: R1 = H, halo, CN; R3, R4 = H, F, Cl; R5 = H, OH, halo, etc.] and their pharmaceutically acceptable salts were prepared. For example, condensation of 5-(4-amino-2-fluorophenoxy)-1H-indazole, e.g., prepared from 5-hydroxyindazole in 2-steps, and 4-chloro-6-(4-pyridinyl)-2-pyrimidinamine, e.g., prepared from isonicotinic acid in 3-steps, afforded phenylaminopyrimidine II in 62% yield. In Rho-Kinase II (ROKs) inhibition assays, 13-examples of compds. I exhibited IC50 values ranging from 1-680 nM, e.g., the IC50 value of phenylaminopyrimidine II was 20 nM. Compds. I were claimed useful for the treatment of cardiovascular diseases.

IT 688779-56-8P 688779-61-5P 688780-14-5P

688781-25-1P 688781-29-5P 688781-33-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of phenylaminopyrimidines as Rho-Kinase II (ROKs) inhibitors for the treatment of cardiovascular diseases)


RN 688779-56-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(4-[(3-amino-1,2-benzisoxazol-4-yl)oxy]-3-fluorophenyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 688779-61-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 688780-14-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 688781-25-1 CAPLUS

CN 4-Pyrimidineacetic acid, 2-amino-6-[(3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 688781-29-5 CAPLUS

CN 4-Pyrimidinebutanoic acid, 2-amino-6-[(3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



RN 688781-33-1 CAPLUS

CN 4-Pyrimidinebutanoic acid, 2-amino-6-[(3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT 688779-62-6P 688779-63-7P 688779-71-7P

688779-77-3P 688779-78-4P 688779-79-5P

688779-82-0P 688779-86-4P 688779-87-5P

688779-88-6P 688779-89-7P 688779-90-0P

688779-93-3P 688779-95-5P 688779-96-6P

688779-97-7P 688779-98-8P 688780-01-0P

688780-02-1P 688780-05-4P 688780-06-5P

688780-07-6P 688780-08-7P 688780-10-1P

688780-11-2P 688780-12-3P 688780-13-4P

688780-15-6P 688780-73-6P 688780-75-8P

688780-77-0P 688780-79-2P 688780-81-6P

688780-83-8P 688781-01-3P 688781-03-5P

688781-05-7P 688781-07-9P 688781-09-1P

688781-11-5P 688781-13-7P 688781-15-9P

688781-17-1P 688781-19-3P 688781-21-7P

688781-23-9P 688781-27-3P 688781-31-9P


688781-35-3P 688781-51-3P 688781-53-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of phenylaminopyrimidines as Rho-Kinase II (ROKs) inhibitors for the treatment of cardiovascular diseases)

RN 688779-62-6 CAPLUS


CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-chloro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)




CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-(1H-indazol-6-yloxy)phenyl]-
(9CI) (CA INDEX NAME)



2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-phenyl-
(9CI) (CA INDEX NAME)




2,4-Pyrimidinediamine, N4-[3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




CN 2,4-Pyrimidinediamine, 6-(4-fluorophenyl)-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)

Nc1nc(cc1Nc2ccc(F)cc2)Oc3ccc4c(c3)ccc5c4NCC5


2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




2,4-Pyrimidinediamine, N4-[3-chloro-4-(1H-indazol-5-yloxy)phenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



2,4-Pyrimidinediamine, N4-[4-[(3-amino-1-methyl-1H-indazol-6-yl)oxy]-3-chlorophenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Nc1ccc(NC(=O)c2cc(F)ccc2)cc1


2,4-Pyrimidinediamine, N4-[3,5-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)oxyphenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




2,4-Pyrimidinediamine, N4-[4-[(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxyl]-3-fluorophenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Nc1nc(N)cc(C2=CC=CC=C2F)n1


CN 2,4-Pyrimidinediamine, N4-[4-[(3-amino-1H-indazol-6-yl)oxy]-3-chlorophenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




CN 2,4-Pyrimidinediamine, N4-[4-[(3-amino-1H-indazol-4-yl)oxy]-3-chlorophenyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




2,4-Pyrimidinediamine, 6-cyclohexyl-N4-(3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)- (9CI) (CA INDEX NAME)




RN 688779-95-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-((3-fluoro-4-((1H-indazol-5-yl)oxy)phenyl)amino)- (9CI) (CA INDEX NAME)




RN 688779-96-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-((3-fluoro-4-((1H-indazol-5-yl)oxy)phenyl)-6-(4-methoxyphenyl))- (9CI) (CA INDEX NAME)




RN 688779-97-7 CAPLUS
CN Benzonitrile, 3-((2-amino-6-((3-fluoro-4-((1H-indazol-5-yl)oxy)phenyl)amino)-4-pyrimidinyl))- (9CI) (CA INDEX NAME)




RN 688780-06-5 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-amino-6-((3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)amino)-, methyl ester (9CI) (CA INDEX NAME)




RN 688780-07-6 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-amino-6-((3-fluoro-4-((1H-indazol-5-yl)oxy)phenyl)amino)-, methyl ester (9CI) (CA INDEX NAME)




RN 688780-08-7 CAPLUS
CN Piperazine, 1-((2-amino-6-((3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)amino)-4-pyrimidinyl)carbonyl)- (9CI) (CA INDEX NAME)




RN 688779-98-8 CAPLUS
CN Benzonitrile, 4-((2-amino-6-((3-fluoro-4-((1H-indazol-5-yl)oxy)phenyl)amino)-4-pyrimidinyl))- (9CI) (CA INDEX NAME)




RN 688780-01-0 CAPLUS
CN 2,4-Pyrimidinediamine, N4-((3-fluoro-4-((1H-indazol-5-yl)oxy)phenyl)-6-(3-nitrophenyl))- (9CI) (CA INDEX NAME)



RN 688780-02-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-((4-bromophenyl)-N4-((3-chloro-4-((1H-indazol-5-yl)oxy)phenyl))- (9CI) (CA INDEX NAME)




RN 688780-05-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-((3-bromophenyl)-N4-((3-chloro-4-((1H-indazol-5-yl)oxy)phenyl))- (9CI) (CA INDEX NAME)



RN 688780-10-1 CAPLUS
CN 6-Oxa-2,9-diazaspiro[4.5]decane, 2-((2-amino-6-((3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)amino)-4-pyrimidinyl)carbonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 688780-09-8
CMF C25 H25 F N8 O3




CH 2


CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 688780-11-2 CAPLUS
 CN Piperazine, 1-[[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 688780-12-3 CAPLUS
 CN 4-Pyrimidinecarboxamide, 2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-N-[2-(1-piperidinylethyl)- (9CI) (CA INDEX NAME)




RN 688780-13-4 CAPLUS
 CN Piperazine, 1-[[2-amino-6-[[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]amino]-4-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 688780-77-0 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 688780-79-2 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 688780-81-6 CAPLUS
 CN Benzenemethanol, 2-[[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 688780-15-6 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3,5-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 688780-73-6 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 688780-75-8 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-[4-(dimethylamino)phenyl]-N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 688780-83-8 CAPLUS
 CN Benzenemethanol, 4-[[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 688781-01-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-[[[1,1-dimethylethyl]amino]methyl]-N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 688781-03-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-6-(1-piperidinylmethyl)]- (9CI) (CA INDEX NAME)




RN 688781-05-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-6-((1-methylcyclopentyl)amino)methyl)]- (9CI) (CA INDEX NAME)




RN 688781-11-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-((cyclopropylamino)methyl)-N4-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)]- (9CI) (CA INDEX NAME)




RN 688781-13-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-([[(1-methylethyl)amino)methyl]-N4-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)]- (9CI) (CA INDEX NAME)




RN 688781-07-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-6-((1,1,3,3-tetramethylbutyl)amino)methyl)]- (9CI) (CA INDEX NAME)




RN 688781-09-1 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-6-((2-methyl-1-piperidinyl)methyl)]- (9CI) (CA INDEX NAME)




RN 688781-15-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-((2,6-dimethyl-1-piperidinyl)methyl)-N4-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)]- (9CI) (CA INDEX NAME)



RN 688781-17-1 CAPLUS
CN 2,4-Pyrimidinediamine, 6-([[(4-fluorophenyl)amino)methyl]-N4-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)]- (9CI) (CA INDEX NAME)




RN 688781-19-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-((propylamino)methyl)- (9CI) (CA INDEX NAME)




RN 688781-21-7 CAPLUS
CN 2,4-Pyrimidinediamine, 6-[[1,1-dimethylethylamino]methyl]-N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 688781-31-9 CAPLUS
CN Piperidine, 1-[4-[2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-4-pyrimidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)




RN 688781-35-3 CAPLUS
CN 4-Pyrimidinebutanol, 2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]- (9CI) (CA INDEX NAME)





RN 688781-51-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-indazol-5-yloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 688781-23-9 CAPLUS
CN 4-Pyrimidinemethanol, 2-amino-6-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 688781-27-3 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 688781-53-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (9CI) (CA INDEX NAME)



IT 688782-22-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenylaminopyrimidines as Rho-Kinase II (ROKs) inhibitors for the treatment of cardiovascular diseases)
RN 688782-22-1 CAPLUS
CN Phenol, 4-[(2-amino-6-chloro-4-pyrimidinyl)amino]-2-chloro- (9CI) (CA INDEX NAME)



IT 91241-38-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylaminopyrimidines as Rho-Kinase II (ROKs) inhibitors for the treatment of cardiovascular diseases)
RN 91241-38-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 2004:20322 CAPLUS
 DOCUMENT NUMBER: 140:87658
 TITLE: Peptidomimetic modulators of cell adhesion
 INVENTOR(S): Gour, Barbara J.; Blazchuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shaomeng; Hu, Zengjian
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 280 pp., Cont.-in-part of U.S. Ser. No. 6,982.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 15
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004006011	A1	20040108	US 2003-425557	20030428
US 6031072	A	20000229	US 1997-893534	19970711
US 6326352	B1	20011204	US 2000-507102	20000217
US 2002168761	A1	20021114	US 2001-769145	20010124
US 2002151475	A1	20021017	US 2001-6982	20011204
US 6914044	B2	20050705		

PRIORITY APPLN. INFO.:
 US 1996-21612P P 19960712
 US 1997-893534 A1 19970711
 US 2000-491078 B2 20000124
 US 2000-507102 A1 20000217
 US 2001-769145 B2 20010124
 US 2001-6982 A2 20011204

OTHER SOURCE(S): MARPAT 140:87658
 AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
 IT 339016-03-4, 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxypheyl)-RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
 RN 339016-03-4 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxypheyl)- (9CI) (CA INDEX NAME)





ACCESSION NUMBER: 2003:1006976 CAPLUS
 DOCUMENT NUMBER: 140:59653
 TITLE: Preparation of phenylaminopyrimidines as rho-kinase inhibitors
 INVENTOR(S): Feurer, Achim; Bennabi, Samir; Heckroth, Heike; Ergueden, Jens; Schenke, Thomas; Bauser, Markus; Kust, Raimund; Stasch, Johannes-Peter; Stahl, Elke; Muentert, Klaus; Lang, Dieter; Ehmeke, Heino
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106450	A1	20031224	WO 2003-EP5827	20030604
WO 2003106450	A8	20050203		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 DE 10226943 A1 20040108 DE 2002-10226943 20020617
 CA 2489452 A1 20031224 CA 2003-2489452 20030604
 AU 2003232848 A1 20031231 AU 2003-232848 20030604
 EP 1515965 A1 20050323 EP 2003-759908 20030604
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005538962 T 20051222 JP 2004-513282 A 20030604
 PRIORITY APPLN. INFO.: DE 2002-10226943 A 20020617
 WO 2003-EP5827 W 20030604


OTHER SOURCE(S): MARPAT 140:59653
 GI



AB Title compds. (I): R1 = amino, OH; R2 = H, alkyl, cycloalkyl; R3, R4 = cyano, H, F, Cl; A = Q1-Q3; R5, R6 = H, F, Cl; D = (substituted) Ph, (iso)quinoline, indole, etc.; were prepared for treating cardiovascular diseases. Thus, 4-chloro-6-quinolin-6-yl-pyrimidin-2-amine (preparation given) and 3-fluoro-4-(4-pyridinylsulfanyl)aniline (preparation given) were treated with 37% HCl followed by stirring for over night at 100° to give 12% N-[2-amino-6-(6-quinolinyl)-4-pyrimidinyl]-N-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]amine. The latter inhibited Rho-kinase II (ROKs) with IC50 = 7 nM.
 IT 637039-06-6P 637039-07-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylaminopyrimidines as rho-kinase inhibitors)
 RN 637039-06-6 CAPLUS
 CN Phenol, 4-[2-amino-6-[(3-fluoro-4-(5-isoquinolinyl)oxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 637039-07-7 CAPLUS
CN Acetamide, N-[3-[2-amino-6-[[3-fluoro-4-(5-isoquinolinylloxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




IT 570415-44-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylaminopyrimidines as rho-kinase inhibitors)
RN 570415-44-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-(5-isoquinolinylloxy)phenyl]- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2003:591171 CAPLUS
DOCUMENT NUMBER: 139:149645
TITLE: Preparation of pyrimidine derivatives for use in pharmaceutical compositions as rho-kinase inhibitors
INVENTOR(S): Nagarathnam, Dhanapalan; Dumas, Jacques; Hatoum-Mokdad, Holias; Boyer, Stephen; Plueme, Hans
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM.: COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062227	A1	20030731	WO 2003-US1840	20030123
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473910	A1	20030731	CA 2003-2473910	20030123
US 2004002507	A1	20040101	US 2003-349176	20030123
US 6943172	B2	20050913		
EP 1470122	A1	20041027	EP 2003-705859	20030123
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005523894	T	20050811	JP 2003-562105	20030123
MX 2004PA07196	A	20050608	MX 2004-PA7196	20040723
US 2005209261	A1	20050922	US 2005-111704	20050422
PRIORITY APPL. INFO.:				
			US 2002-349986P	P 20020123
			US 2003-349176	A3 20030123
			WO 2003-US1840	W 20030123

GI




II

AB Pyrimidine derivs., such as I [R = H, Ph; R1 = H, alkyl, aryl, heteroaryl,




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


halogens; R2 = H, alkyl, halogens; R1R2 = (CH2)3-5; R3 = heteroaryl, such as pyridinyl, quinolinyl or isoquinolinyl; X = O, S; R4, R5 = H, Cl, F, were prepd. for therapeutic use as rho-kinase inhibitors. These pyrimidine derivs. are useful for inhibiting tumor growth in cancer of the breast, colon, prostate, ovaries, brain or lung, and for treatment of other disorders mediated by rho-kinase, such as erectile dysfunction, coronary heart disease, hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neuronal degeneration, spinal cord injury, asthma, glaucoma and osteoporosis. Thus, II was prepd. in 18% yield by reacting 2-amino-4-chloro-6-methylpyrimidine with 3-fluoro-4-(4-pyridinylthio)aniline using K2CO3 in o-xylene at 100° overnight. The prepd. pyrimidine derivs. were assayed for inhibition of ROCK-1 phosphorylation of myelin basic protein.
IT 570415-18-8P 570415-24-6P 570415-31-5P 570415-33-7P 570415-44-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. for use in pharmaceutical compns. as rho-kinase inhibitors)
RN 570415-18-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(5-isoquinolinylloxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 570415-24-6 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(5-isoquinolinylloxy)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 570415-31-5 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-fluoro-4-(5-isoquinolinyl)oxy]phenyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 570415-33-7 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[3,5-dichloro-4-(5-isoquinolinyl)oxy]phenyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 570415-44-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-[3-fluoro-4-(5-isoquinolinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:591169 CAPLUS
DOCUMENT NUMBER: 139:149643
TITLE: Preparation of pyrimidinamines as Rho-kinase inhibitors for inhibiting tumor growth, treating erectile dysfunction, and other therapeutic uses
INVENTOR(S): Nagarathnam, Dhanapalan; Dumas, Jacques; Hatoum-mokdad, Holis; Boyer, Stephen; Wang, Chunguang; Plueme, Hans; Feurer, Achim; Bennabi, Samir
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062225	A1	20030731	WO 2003-US1839	20030123
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2473510	A1	20030731	CA 2003-2473510	20030123
US 2004002508	A1	20040101	US 2003-349177	20030123
US 6924290	B2	20050802		
EP 1470121	A1	20041027	EP 2003-705858	20030123
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005521659	T	20050721	JP 2003-562103	20030123
MX 2004PA07191	A	20050331	MX 2004-PA7191	20040723
US 2005192304	A1	20050901	US 2005-107793	20050418
PRIORITY APPLN. INFO.:			US 2002-349987P	P 20020123
			US 2003-349177	A3 20030123
			WO 2003-US1839	W 20030123

OTHER SOURCE(S): MARPAT 139:149643
GI




AB Disclosed are pyrimidinamines (shown as I; variables defined below; e.g. 4-[(4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl)sulfanyl]phenol], their synthesis, and their use as Rho-kinase inhibitors (no data). These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. For I: R1 and R2 = H, halo, alkyl (un)substituted

by halo up to perhalo, cycloalkyl, alkenyl, alkynyl, NO₂, NH₂, NR₆R₇, or furyl, thienyl, pyridyl, trifluoromethyl or Ph each (un)substituted with NH₂, NO₂ trifluoromethyl or alkoxy; or R1 and R2 may be taken together to form a ring of = 5-7 members optionally interrupted by N and (un)substituted on N by benzyl. R3 = NH₂ or -NH- Ph (un)substituted with halo, Cl-C4 alkyl, trifluoromethyl, nitro or amino; R4 = X-A- and R5n-substituted Ph, R5n-substituted 6-X-Apyridin-3-yl or indol-5-yl (un)substituted on N with pyridyl; X is a linker substituted at the 3 or 4 position of the ring and is O, S, -S-CH₂-, -(CH₂)n-, or -C(O)-. A is Ph (un)substituted with alkylthio or OH, pyridyl, quinolyl or isoquinolyl. Each R5 independently is halo, alkyl (un)substituted by halo up to perhalo, cycloalkyl, alkoxy, alkenyl, alkynyl, NO₂, NH₂, or trifluoromethyl; n is 0-4; m is 1 or 2; and R6 and R7 are each independently H, alkyl, cycloalkyl, or Ph (un)substituted with halo, CF₃, alkyl, nitro or amino; or R6 and R7 may form, together with the N atom to which they are attached, a heterocyclic ring (un)substituted with alkyl, optionally interrupted by O, or optionally fused to phenyl; addn. details including provisos are given in the claims. More than 30 example preps. of 1 plus many preps. of intermediates are included. For example, 4-[(4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl)mercapto]phenol (0.11 mmol, 51% yield) was prepd. from 2-amino-4-chloro-6-ethylpyrimidine (0.23 mmol) and 4-[(4-aminophenyl)sulfanyl]phenol (0.25 mmol) suspended in a mixt. of 0.01M aq. HCl (230 µL) and 1-butanol (230 µL); the mixt. was refluxed overnight.


IT 569658-24-8P, 4-[(4-[(4-Hydroxyphenyl)phenyl]amino)-6-methylpyrimidin-2-amine 569658-28-2P, N-(2-Amino-6-methyl-4-pyrimidinyl)-N'-[4-[(5-quinolinyl)oxy]phenyl]amine
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidinamines as Rho-kinase inhibitors for inhibiting tumor growth, treating erectile dysfunction, and other therapeutic uses)

RN 569658-24-8 CAPLUS
CN Phenol, 4-[(4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenoxyl)- (9CI) (CA INDEX NAME)





RN 569658-28-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-[4-(5-quinolinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:927396 CAPLUS
DOCUMENT NUMBER: 138:13955
TITLE: Preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase for the treatment of disease
INVENTOR(S): Cao, Sheldon Xiaodong; Bounaud, Pierre-Yves; Chen, Xiaohua; Chung, Hyun-Ho; Dumas, David Paul; Ko, Sunil Kumar; Min, Changhee; Yang, Jae Young; Long, Melissa C.
PATENT ASSIGNEE(S): LG Biomedical Institute, USA
SOURCE: PCT Int. Appl., 286 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096867	A2	20021205	WO 2002-US16920	20020528
WO 2002096867	A3	20040304		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002310187	A1	20021209	AU 2002-310187	20020528
US 2003187007	A1	20031002	US 2002-158030	20020528
US 2003208067	A1	20031106	US 2002-158103	20020528
EP 1412327	A2	20040428	EP 2002-737248	20020528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534779	T	20041118	JP 2003-500047	20020528
KR 2004026657	A	20040331	KR 2003-715388	20031125
PRIORITY APPLN. INFO.:				
US 2001-294792P P 20010530				
WO 2002-US16920 W 20020528				
OTHER SOURCE(S): MARPAT 138:13955				
GI				




AB Phenol and hydroxynaphthalene derivs. I [X = O, S, amine, alkylamine, alkynylamine, arylamine, and heteroarylamine; R1 = (un)substituted 5- or 6-membered aromatic or heteroarom. ring, -(X1)mCOX2, wherein X1 = alkylene, alkynylene, alkynylene, aryl and heteroaryl; X2 = H, alkyl, aryl, heteroaryl, OH, alkoxy, amino, substituted amine, m = 0 or 1, or R1 = -C(X3)-N-NX4-C(E)-NX5X6 wherein X3 = H, alkyl, aryl, alkylaryl, heteroaryl, and amino and E = O, S, and substituted amine with X4, X5, and X6 independently equal to H, alkyl, aryl, and heteroaryl; R2, R3, and R4 = H, alkyl, alkylene, halo, alkoxy, etc.; or R2 and R3 or R3 and R4 may be taken together to form an (un)substituted aromatic or heteroarom. ring; R5 = H, (un)substituted-alkyl, -aryl, -heterocycle, etc.; R6 = H, alkyl, alkene, alkyne, aryl, and heteroaryl] are prepared and disclosed as inhibitors of protein kinase. Thus, II was prepared by cyclocondensation of 5'-bromo-2'-methoxyacetophenone with N,N-dimethylformamide di-Et acetal with subsequent Suzuki coupling with 4-methoxyphenylboronic acid. In assays to determine cyclin dependent kinase activity, specifically against

CDK2 and CDK5, II possessed IC50 values of 0.0-0.5 μ M. II proved highly specific for CDK2 and CDK5 and was further evaluated by in vitro tumor cell efficacy tests against numerous cancers. The present invention is directed in part towards methods of modulating the function of protein kinases with phenol- and hydroxynaphthalene-based compds. The methods incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compds. and pharmaceutical compds. comprising these compds.

IT 477727-07-4P 477727-28-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase)
RN 477727-07-4 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 477727-28-9 CAPLUS
CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(2-fluoro-4-hydroxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:869496 CAPLUS
DOCUMENT NUMBER: 137:363033
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shaoemeng; Hu, Zengjian
PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.
SOURCE: CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002168761	A1	20021114	US 2001-769145	20010124
US 2004058864	A1	20040325	US 2003-412701	20030410
US 2004006011	A1	20040108	US 2003-425557	20030428

PRIORITY APPLN. INFO.:
US 2000-491078 A2 20000124
US 1996-21612P P 19960712
US 1997-893534 A1 19970711
US 2000-507102 A1 20000217
US 2001-769145 B1 20010124
US 2001-6992 A2 20011204


OTHER SOURCE(S): MARPAT 137:363033
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
IT 339016-03-4, 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphe-nyl)-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
RN 339016-03-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphe-nyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:651318 CAPLUS
DOCUMENT NUMBER: 117:251318
TITLE: Novel piperazinyl-substituted pyrimidines as antihypertensive and vasodilators
AUTHOR(S): Badran, M. M.; Youssef, K.
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Revue Roumaine de Chimie (1992), 37(2), 283-8
CODEN: RRCBAX; ISSN: 0035-3930
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Three series of piperazinyl-substituted pyrimidine derivs. having the general formulas I, II, and III (R = 2-ETOC6H4, 2-MeOC6H4, 2-ClC6H4, 4-ClC6H4, 3-CF3C6H4, PhCH2) were synthesized. Reaction of 2-amino-4-chloro-6-methylpyrimidine (IV) with a number of 1-arylpiperazines afforded the corresponding 4-aryl-1-piperazinyl-substituted pyrimidines I. The second series was prepared by treating 2-amino-4-(p-carboxyanilino)-6-methylpyrimidine (V, R1 = CO2H), prepared via reaction of IV and p-aminobenzoic acid, with thionyl chloride to give the corresponding key intermediate V (R1 = COCl). The latter was treated with the appropriate 1-arylpiperazines to furnish the desired products II. Adnll., the third series of target compds. III was prepared by reacting IV with 4-aminophenol to give V (R1 = OH). Application of the acid-catalyzed Mannich reaction to V (R1 = OH), using formaldehyde and different 1-arylpiperazines gave the corresponding Mannich bases III.
IT 131555-97-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Mannich reaction of, with formaldehyde and arylpiperazines)
RN 131555-97-0 CAPLUS
CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:545724 CAPLUS
DOCUMENT NUMBER: 135:147398
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shaoemeng; Hu, Zengjian
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Can.
SOURCE: PCT Int. Appl., 416 pp.
CODEN: P1XXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053331	A2	20010726	WO 2001-US2508	20010124
WO 2001053331	A3	20020711		
WO 2001053331	A9	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: MARPAT 135:147398
US 2000-491078 A 20000124


OTHER SOURCE(S): MARPAT 135:147398
AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
IT 339016-03-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)
RN 339016-03-4 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-phenoxyphe-nyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:81760 CAPLUS
DOCUMENT NUMBER: 114:81760
TITLE: Novel piperazinyl-substituted pyrimidines as possible antihypertensive and vasodilators
AUTHOR(S): Badran, M. M.; Youssef, K.
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Egyptian Journal of Pharmaceutical Sciences (1990), 31(1-4), 407-15
CODEN: EJP5BZ; ISSN: 0301-5068
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The preparation of 3 series of title compds. I (Z = bond, R = 3-EtO, 4-Cl, 2-Cl, 3-CF3; Z = CH2, R = H), II (Z = bond, R = 2-MeO, 4-Cl, 2-Cl, 3-CF3; Z = CH2, R = H) and III (Z = bond, R = 2-Cl, 4-Cl, 2-EtO; Z = CH2, R = H) from 2-amino-4-chloro-6-methylpyrimidine is reported.
IT 131555-97-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Mannich reaction of, with arylpiperazines and formaldehyde)
RN 131555-97-0 CAPLUS
CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L4 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 1991:62037 CAPLUS
DOCUMENT NUMBER: 114:62037
TITLE: Synthesis of some Mannich bases of 2- and 4-amino- and 2,4-diamino-6-methylpyrimidines as potential biodynamic agents
AUTHOR(S): Ghonaim, Khadiga M.; El-Telbany, Farag A.; Youssef, Khairia
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Egyptian Journal of Chemistry (1989), Volume Date 1987, 30(6), 295-304
CODEN: EGJCA3; ISSN: 0367-0422
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of certain Mannich bases of 2- and 4-amino- and 2,4-diamino-6-methylpyrimidines and their antimicrobial and antileukemic activities are described. Likewise, application of the Mannich conditions to 2-amino-4-(p-hydroxyanilino)-, 4-amino-2-(p-hydroxyanilino)-, and 2-amino-4-(p-acetylanilino)-6-methylpyrimidines using piperazine as the secondary amine afforded the corresponding bis-Mannich bases.
IT 131554-44-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antileukemia activity of)
RN 131554-44-4 CAPLUS
CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



IT 131555-97-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antibacterial and antifungal activity of)
RN 131555-97-0 CAPLUS
CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-, monohydrochloride (9CI). (CA INDEX NAME)




• HCl

L4 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 1964:46427 CAPLUS
DOCUMENT NUMBER: 61:64427
ORIGINAL REFERENCE NO.: 61:11197f-g
TITLE: Growth inhibition of Clostridium fesiari by carcinostatic purine and pyrimidine analogs. I. Effect of medium on growth inhibition
AUTHOR(S): Cappuccino, James G.; George, Marilyn; Merker, Philip C.; Tarnowski, George S.
CORPORATE SOURCE: Sloan-Kettering Inst., New York, NY
SOURCE: Cancer Research (1964), 24, 1243-8
CODEN: CNREAH; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable


AB C. fesiari grows well, in semisynthetic basal medium devoid of purine bases and folic acid. Growth inhibition of this organism is pronounced in such a medium by carcinostatic purine analogs; with pyrimidine analogs, inhibition is also marked. Purines in the medium block the growth inhibition caused by purine analogs. Greater agreement occurs between the growth inhibition of the organism and that of adenocarcinoma 755 when carcinostatic purine and pyrimidine analogs are studied in purineless media as compared with complex thioglycolate medium.
IT 93001-35-5, Pyrimidine, 2-amino-4-p-anisidino-6-methyl- (Clostridium fesiari growth inhibition by)
RN 93001-35-5 CAPLUS
CN Pyrimidine, 2-amino-4-p-anisidino-6-methyl- (7CI) (CA INDEX NAME)



L4 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 1975:579000 CAPLUS
DOCUMENT NUMBER: 83:179000
TITLE: Purine Antagonists. II. Synthesis of 2,6-disubstituted 9-arylpurines and 9-aryl-8-azapurines and some related 5-phenylazopyrimidines
AUTHOR(S): Sen, D.; Sengupta, Purnendu
CORPORATE SOURCE: Univ. Coll. Sci. Technol., Calcutta Univ., Calcutta, India
SOURCE: Indian Journal of Chemistry (1975), 13(6), 549-51
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 83:179000
GI For diagram(s), see printed CA issue.
AB 2-Amino-6-hydroxy-9-arylpurines I (R = Me, MeO; R = H2N) were prepared by the cyclization of 2,5-diamino-6-arylamino-4-hydroxypyrimidines with HCONH2. 9-Aryl-2,6-dihydroxypurine I (R = MeO, R1 = OH) were prepared by the deamination of 2-amino-9-aryl-6-hydroxypurine with NaNO2 and concentrate HCl. 9-Aryl-8-azapurines II (R = Me, MeO) were prepared by the cyclization of 2,5-diamino-6-arylamino-4-hydroxypyrimidines with NaNO2 and HOAc. 2,5-Diamino-6-arylamino-4-hydroxypyrimidines were obtained by the reduction of 2-amino-6-arylamino-4-hydroxy-5-phenylazopyrimidines with sodium dithionite. The preparation of 5-phenylazopyrimidines III (R = Me, R2 = MeO) involves the reaction of appropriate 2-amino-6-arylamino-4-hydroxypyrimidines with benzenediazonium chloride.
IT 57493-60-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with benzenediazonium chloride)
RN 57493-60-4 CAPLUS
CN 4-(1H)-Pyrimidinone, 2-amino-6-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN


ACCESSION NUMBER: 1962:429651 CAPLUS
DOCUMENT NUMBER: 57:29651
ORIGINAL REFERENCE NO.: 57:5916d-1, 5917a
TITLE: Pyrimidines. VII. 2-Amino-4-(substituted anilino)pyrimidines
AUTHOR(S): O'Brien, Darrell E.; Baiocchi, Fred; Robins, Roland K.; Cheng, C. C.
CORPORATE SOURCE: Midwest Res. Inst., Kansas City, MO
SOURCE: Journal of Organic Chemistry (1962), 27, 1104-7
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 57:29651
GI For diagram(s), see printed CA issue.

AB An appropriate chloropyrimidine (0.1 mole) and 0.1 mole suitable aniline mixed with 1 ml. concentrated HCl in a round-bottom flask and immersed in an oil bath at 175° (exothermic reaction at 155° with rise of temperature to 185°), the mixture heated 20 min. at 185° and the cooled glass-like mass taken up in 200 ml. dilute HCl, the clarified (C) solution filtered and made alkaline with NH4OH, the precipitate dried at 80° and recrystd. from H2O and alc. gave the alkylaminopyrimidines (I, Z = NH2, Me, Cl). HOCH2CH2OH (150 ml.), 10 g. NaOH, and 10 g. I (Z = Cl) in a round-bottom flask heated at 160° (preheated oil bath) with exothermic reaction, heated 30 min. at 175° and the cooled solution taken up in 500 ml. H2O, the clarified filtrate heated and acidified with AcOH, filtered hot and the dried product recrystd. gave I (Z = OH). A similar procedure using NaSH in place of NaOH gave I (Z = SH). The comps. synthesized are tabulated (R = H except where indicated) (series, X, Y, % yield, and m.p. given): Z = NH2: H, H, 78, 172-4°; H, H, Me, 72, 193-4°; H, 2-Me, 79, 182-3°; H, 3-Me, 76, 129-30°; H, 4-Me, 84, 172-3°; H, 4-MeO, 87, 179-80°; H, 4-HOC2H4, 81, 146-8°; H, 4-F, 81, 175-7°; H, 2-Cl, 71, 175-6°; H, 3-Cl, 78, 1601°; H, 4-Br, 90, 175-6°; 3-Me, 4-Me, 83, 163-4°; 4-Me, 3-Cl, 87, 172-3°; 3-Cl, 4-Cl, 92, 185-6°; Z = Me: H, H, Me, 74, 148-9°; H, H, HOC2H4, 67, 162-3°; H, 3-Me, 83, 142-3°; H, 4-Me, 91, 224-5°; H, 4-MeO, 89, 222-3°; H, 3-EtO, 64, 159-60°; H, 4-HOCH2CH2, 80, 204-5°; H, 2-Cl, 67, 175-7°; H, 3-Cl, 59, 147-8°; H, 2-Br, 78, 1723°; H, 4-Br, 88, 227-8°; H, 4-CN, 53, 215-16°; 2-Me, 5-Me, 67, 191-2°; 3-Me, 4-Me, 88, 213-14°; 4-Me, 3-Cl, 81, 185-6°; 3-Cl, 4-Cl, 96, 206-7°; Z = Cl: H, H, Me, 68, 177-8°; H, 2-Me, 54, 230-1°; H, 3-Me, 66, 166-7°; H, 4-Me, 78, 236-8°; H, 4-MeO, 74, 213-15°; H, 2-EtO, 77, 153-4°; H, 4-HOC2H4, 73, 191-2°; H, 2-Cl, 76, 1889°; H, 3-Cl, 74, 154-5°; H, 2-Br, 63, 194-5°; H, 4-Br, 84, 246-8°; H, 4-CN, 52, 279-81°; 3-Me, 4-Me, 78, 2279°; 4-Me, 3-Cl, 78, 197-9°; 3-Cl, 4-Cl, 81, 216-17°. Z = OH: H, 2-Me, 70, 264-5°; H, 4-Me, 83, 262-3°; H, 4-MeO, 80, 295-7°; H, 2-Cl, 71, 273-4°; H, 3-Cl, 73, 25960°; H, 4-Br, 82, 296-8°; 3-Me, 4-Me, 87, 218-20°; 4-Me, 3-Cl, 81, 307-9°; 3-Cl, 4-Cl, 85, 258-9°. Z = SH: H, 2-Me, 63, 259-60°; H, 3-Me, 81, 224-6°; H, 4-Me, 85, 284-5°; H, 4-MeO, 79, 238-9°; H, 2-Cl, 67, 237-8°; H, 3-Cl, 80, 285-6°; 3-Me, 4-Me, 83, 220-2° (decomposition); 4-Me, 3-Cl, 80, 261-2° (decomposition); 3-Cl, 4-Cl, 85, 288-9° (decomposition). Ultraviolet spectral data were tabulated.
IT 57493-60-4P, 4-Pyrimidinol, 2-amino-6-p-anisidino-91241-38-2P, Pyrimidine, 2-amino-4-p-anisidino-6-chloro-


L4 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
93001-35-5P, Pyrimidine, 2-amino-4-p-anisidino-6-methyl-
RL: PREP (Preparation)
RN 57493-60-4 CAPLUS
CN 4 (1H)-Pyrimidinone, 2-amino-6-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 91241-38-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 93001-35-5 CAPLUS
CN Pyrimidine, 2-amino-4-p-anisidino-6-methyl- (7CI) (CA INDEX NAME)




L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
in 700 ml. cold EtOH added dropwise during 3 hrs. to VIII (from 14.3 g. VI, 50 ml. concd. HCl, 200 ml. EtOH, 80 ml. H₂O, and 9.52 g. NaNO₂) at 0-5° with stirring, stirred 3 hrs. more, stored overnight at 5°, the ppt. filtered off, washed twice with 50-ml. portions H₂O, and dried 5 hrs. in vacuo at 80° gave 7.0 g. IX (R = C₆H₄OMe-p) (X), m. 282-3° (uncor.) (EtOH-MeOCH₂CH₂OH). IX (R = Et) (25.2 g.), 625 ml. EtOH, 625 ml. H₂O, and 62.5 ml. AcOH heated to 70° with stirring under N, the mixt. treated portionwise during 1 hr. with 60 g. Zn dust, heated 1 hr. at 70°, filtered while hot, the filter cake washed with 3 20-ml. portions EtOH, the combined filtrate and washings concd. in vacuo under N to 350 ml., and cooled to room temp. gave 11.3 g. XI (R = Et), m. 207-8° (uncor.) (EtOH). IX (R = Et) (1.0 g.) in 20 ml. EtOH treated dropwise during 15 min. with 2.75 g. SnCl₂·2H₂O in 20 ml. concd. HCl with stirring under N, the mixt. heated 45 min. at 55-60°, the resulting soln. cooled to room temp., treated with 16 g. NaOH in 40 ml. H₂O, and kept 1 hr. gave 710 mg. crude X (R = Et); sublimation of 200 mg. crude product gave 130 mg. XI (R = Et), m. 208-9° (uncor.) (EtOH). Redn. of IX (R = Et) with Fe powder and HCl in EtOH-AcOH-H₂O gave 711 XI (R = Et), m. 209-12° (uncor.) (EtOH) (50.4 g.) reduced as above with 120 g. Zn dust in 1260 ml. EtOH, 1260 ml. H₂O, and 126 ml. AcOH, the mixt. filtered under N, the filtrate cooled in an ice bath, made alk. to pH 9-10 with 420 ml. 6N NaOH, treated with C and Celite, filtered through Celite under N, the filtrate neutralized to pH 7 with 32 ml. AcOH, concd. in vacuo at below 40° to 1.5 l., cooled at 5°, the ppt. collected, washed with 2 30-ml. portions H₂O, and stirred twice with 100-ml. portions 1:1 cyclohexane-iso-Pr₂O gave 29.2 g. crude XI (R = Bu), m. 106-7°. Crude XI (R = Bu) (10.6 g.) dissolved in 120 ml. N HCl, the filtered soln. adjusted to pH 5, treated with C, filtered, the filtrate adjusted to pH 9 with 6N NaOH, and chilled gave 6.7 g. XI (R = Bu), m. 125-6° (sublimation in vacuo). Redn. of X with Zn as above gave (in 2 crops) 751 XI (R = C₆H₄OMe-p) (XII), m. 158-60° (decompn.). XI (R = Et) (11.3 g.) in 900 ml. H₂O and 180 ml. AcOH treated dropwise during 1 hr. with 4.65 g. NaNO₂ in 20 ml. H₂O at 0-5° with stirring and the mixt. stirred 1 hr. at 0-5° gave 9.4 g. XIII (R' = Cl, R = Et) (XIV), m. 159-60°. Similarly was prepd. 824 XIII (R' = Cl, R = Bu) (XV), m. 88-9° (iso-Pr₂O-cyclohexane). Redn. of IX (R = Bu) with Zn, the excess Zn filtered off, and the filtrate treated with 2.05 g. equivs. NaNO₂ at 0-5° gave a red product from which some XV was obtained after laborious purification; a small amt. of XIII (R' = NHCH₂CH₂OH, R = Bu) (XVI) was also isolated. A soln. of XII (prepd. by reducing 2.5 g. X and removing the excess Zn by filtration under N) treated during 1 hr. with 945 mg. NaNO₂ and 6.5 ml. AcOH at 0-5° under N gave 1.21 g. XIII (R' = Cl, R = C₆H₄OMe-p), m. 267-9° (decompn.) (EtOAc with C). XIV (3.1 g.), 250 ml. EtOH, and 75 ml. N NaOH refluxed and stirred 7 hrs., the soln. concd. to 100 ml., and acidified (pH 4.8) with concd. HCl gave 2.3 g. XVII (R = Et), m. 296-7° (decompn.) (uncor.) (EtOH). Similarly was prepd. 861 XVII (R = Bu), m. 290-2° (decompn.) (uncor.) (obtained by acidification of the reaction mixt.), and another form m. 284-5° (decompn.) (uncor.) (EtOH); the 2 forms were identical (by paper chromatography and ultraviolet absorption spectra in EtOH). XIV (7.0 g.) in 400 ml. dry EtOH added to NaOEt soln. (prepd. from 1.214 g. Na and 80 ml. dry EtOH), the mixt. heated to 70°, kept 10 min. at 70°, cooled, acidified (pH 4-5) with concd. HCl, evapd. in vacuo, the residue leached with 2 500-ml. portions hot C₆H₆, and the combined C₆H₆ solns. evapd. gave 4.9 g. XIII (R' = OEt, R = Et), m. 120° (1:1 C₆H₆-cyclohexane). Na (5.75 g.) in 300 ml. abs. EtOH secd. with H₂O during 1.5 hrs., the soln. treated with 6.5 g. XIV, refluxed 2 hrs. (the reaction was conducted in a flask equipped with a H₂O-cooled condenser surmounted by a Dewar-type condenser contg. solid CO₂ and moisture was

L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1962:73486 CAPLUS
DOCUMENT NUMBER: 56:73486
ORIGINAL REFERENCE NO.: 56:14277-1, 14278a-1, 14279a-1, 14280a
TITLE: v-Triazolo[4,5-d]pyrimidines. 1. Synthesis and nucleophilic substitution of 7-chloro derivatives of 3-substituted v-triazolo[4,5-d]pyrimidines
AUTHOR(S): Shealy, Y. Fulmer; Struck, Robert F.; Clayton, Joe D.; Montgomery, John A.
CORPORATE SOURCE: Southern Research Inst., Birmingham, AL
SOURCE: Journal of Organic Chemistry (1961), 26, 4433-40
CODEN: JOCEAH; ISSN: 0022-3263
JOURNAL: Journal
LANGUAGE: Unavailable
GI: For diagram(s), see printed CA issue.
AB 3-Substituted 5-amino-7-chloro-v-triazolo[4,5-d]pyrimidines were synthesized from the appropriate 2,5-diamino-4-chloro-6-alkyl (or aryl)aminopyrimidines. Retention of the Cl group until the v-triazolo[4,5-d]pyrimidine ring had been formed permitted introduction, by nucleophilic displacement, of a wide variety of substituents at position 7. (All m.ps. are corrected unless otherwise noted.) BUNH2 (6.14 g.), 6.56 g. 2-amino-4,6-dichloropyrimidine (I), and 120 ml. absolute EtOH refluxed and stirred 6 hrs., the solution concentrated in vacuo to 40 ml., treated slowly with 40 ml. H₂O with stirring, seeded, treated dropwise with an addnl. 40 ml. H₂O with stirring, the precipitate collected, washed with 351 aqueous EtOH and H₂O, and dried in vacuo at 40° gave 7.3 g. II' (R = Bu), m. 97-8° (cyclohexane). I (56.1 g.), 250 ml. absolute EtOH, and 250 ml. EtOH-EtNH₂ (prepared from 148 g. anhydrous EtNH₂ and 830 ml. absolute EtOH) refluxed 2 hrs. (in a flask equipped with a H₂O-cooled condenser surmounted by a Dewar-type condenser containing solid CO₂, and the reaction mixture was protected from moisture), treated with the remainder of the EtNH₂ solution, the solution refluxed 4 hrs., concentrated in vacuo to 175 ml., and chilled gave 43.6 g. (an addnl. 10.1 g. was isolated from the filtrate by dilution with H₂O) II' (R = Et), m. 149° and 154° (after cooling and then remelting) (iso-PrOH). 3 (EtOH) 239 and 284 mp. [α + 10.3 10.8 and 8.5]. Fusion of equimolar amts. I, p-MeOC₆H₄NH₂ (III) and AcOH gave 531 II' (R = C₆H₄OMe-p) (IIIIa), m. 223-4°. I (10 g.), 30 g. III, and 200 ml. EtOH refluxed 5.5 hrs., the precipitate filtered off, washed several times with N HCl, boiled briefly with 150 ml. N HCl, and dried in vacuo gave (in 2 crops) 19.5 g. IV (R = OMe) HCl salt (V.HCl), m. 257-61° (uncor.) (EtOH with C). Crude V.HCl in EtOH made alkaline with aqueous NaOH, concentrated, and the precipitate leached with hot EtOAc gave V, m. 195-6° and 203-4° (after cooling and then remelting) (EtOAc). Similarly, with a 10-fold excess p-ClC₆H₄NH₂ (VI), was prepared IV (R = Cl) HCl salt monohydrate (VII.HCl.EtOH), m. 298-301° (uncor.); VII m. 193° (EtOAc). A cold (0-5°) solution of p-ClC₆H₄NH₂ (VIII) (prepared from 39.4 g. VI, 23.8 g. NaNO₂, 86 ml. concentrated HCl, and 245 ml. H₂O) added dropwise during 6.5 hrs. to 48.7 g. II' (R = Et), 424 g. NaOAc, 1410 ml. AcOH, and 1175 ml. H₂O with stirring under N, and stirred 11.5 hrs. at room temperature under N gave 73.2 g. IX (R = Et), m. 263-4° (decomposition) (uncor.) (EtOAc-Me₂CO-C₆H₆, then EtOAc). Similarly was prepared 70-924 IX (R = Bu), m. 197-8° (uncor.) (iso-PrOH). IIIa (7.0 g.) and 140 ml. pyridine

L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
excluded), dild. with 100 ml. H₂O, treated with C, filtered, the filtrate acidified to pH 2, the ppt. filtered off, washed with H₂O, and dried in vacuo at 50° gave crude 4.1 g. XIII (R' = SH, R = Et) (XVIII), m. 200-2° (decompn.) (uncor.); anal. sample (by reprecip. from 0.5N NaOH with acid, then EtOH) m. 210° (uncor.) (Kofler) and 199-201° (uncor.) (capillary). Similarly was prepd. 824 XIII (R' = SH, R = Bu), m. 193° [by reprecip. from 0.5N NaOH with acid, or MeOCH₂CH₂OH (XIX)-EtOH]. IX (5.67 g. XVII), 4.39 g. K₂CO₃, and 100 ml. HCONMe₂ was added 3.65 ml. PhCH₂Cl in 3 portions; the mixt. heated to 50°, kept 1 hr. at 50-5°, cooled, poured into 600 ml. H₂O, the resulting oil induced to crystallize, the solid (7.8 g.) dissolved in 60 ml. hot EtOH, the soln. treated with C, filtered, the hot filtrate dild. with 40 ml. H₂O, and allowed to cool to give 5.25 g. XIII (R' = SCH₂Ph, R = Et), m. 102° (EtOH-H₂O). N₂H₄·H₂O (2.80 g.) added to 6.00 g. XV in 400 ml. anhyd. EtOH with stirring, the mixt. stirred 1 hr. at room temp., and chilled in an ice bath gave 5.10 g. XIII (R' = NHNH₂, R = Bu) (XX), m. 195° (uncor.) (EtOH). XIV (400 mg.) and 8 ml. (iso-PrO)P heated 7 hrs. at 168°, kept 3 days at 0-5°, the ppt. filtered off, slurried twice with 25-ml. portions hexane, dried in vacuo at 55°, and recrystd. from 1:1 C₆H₆-cyclohexane gave 423 mg. XIII (R' = PO(OPr-iso)2, R = Et) (XXI), m. 119-20° (C₆H₆-cyclohexane). XXI (100 mg.) and 5 ml. N HCl refluxed 1 hr., freeze-dried, and the residue treated with 3 ml. EtOH gave 20 mg. XIII (R' = PO(OH)2, R = Et), m. 284-5° (uncor.) (3:1 EtOH-H₂O). XIV (500 mg.) and 25 ml. EtOH secd. with NH₃ heated 4 hrs. at 95-100° in a 40 ml. stainless steel bomb gave 330 mg. XIII (R' = NH₂, R = Et) (XXII), m. 263-4° (uncor.) (EtOH). XIV (500 mg.), 40 g. 25% aq. Me₂NH, and 50 ml. EtOH refluxed 2.5 hrs. (the app. was topped by a Dewar-type condenser contg. solid CO₂) and the soln. concd. to 20 ml. gave 470 mg. XIII (R' = NMe₂, R = Et) (XXIII), m. 198-9° (EtOH). By procedures used to prep. XXII and XXIII was prepd. 911 and 881, resp., XIII (R' = NH₂, R = Bu) (XXIV), m. 256-9° (uncor.) (XIX-EtOH). XV (300 mg.), 300 mg. (HOCH₂CH₂)₂NH, and 15 ml. anhyd. EtOH refluxed 4 hrs., the soln. treated with C, filtered, the filter cake washed with 5 ml. EtOH, the combined filtrate and washings concentrated in vacuo, the residual slurr. evapd. twice with 10 ml. portions EtOH, the resulting solid residue triturated with 10 ml. H₂O, filtered off, washed with 5 ml. H₂O, and dried in vacuo at 100° gave 325 mg. XIII (R' = N(CH₂CH₂OH)₂, R = Bu), m. 124-5° (EtOAc). Similarly were prepd. 961 XIII (R' = NHCH₂CH₂OH, R = Et), m. 210° (HCONMe₂-EtOH) (45 min. reflux period used); 781 XIII (R' = NHCH₂CH₂NEt₂, R = Et), m. 168-9° (EtOH) (excess Et₂NCH₂CH₂NEt₂ used); and 891 XIII (R' = NHBu, R = Bu) (XXV), m. 160° (50% EtOH) (the evapd. in vacuo, the residual slurr. evapd. twice with 10 ml. portions EtOH, the resulting solid residue triturated with 10 ml. H₂O, filtered off, washed with 5 ml. H₂O, and 250 ml. anhyd. EtOH refluxed 4 hrs. under anhyd. conditions, the mixt. dild. with 50 ml. H₂O, chilled, filtered, and the filtrate concd. to 40 ml. gave 6.65 g. XIII (R' = histaminyl, R = Bu) (XXVI), m. 193-4° (50% EtOH). Similarly was prepd. 841 XVI, m. 233° (EtOH). Ultraviolet absorption data for the 3H-v-triazolo[4,5-d]pyrimidines were tabulated. Preliminary tests indicated that XX, XXV, and XXVI had moderate activity against sarcoma 180 in mice and that XV and XXIV were active against adenocarcinoma 755.
IT 91241-38-2P, Pyrimidine, 2-amino-4-p-anisidino-6-chloro-
RL: PREP (Preparation)
RN 91241-38-2 CAPLUS
CN 2,4-Pyrimidinediamine, 6-chloro-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1960:87613 CAPLUS
 DOCUMENT NUMBER: 54:87613
 ORIGINAL REFERENCE NO.: 54:16655a-d
 TITLE: The schistosomicidal and toxic effects of some N-(p-aminophenoxyalkyl)amides
 AUTHOR(S): Collins, R. F.; Davis, M.; Edge, N. D.; Hill, J.; Reading, H. W.; Turnbull, Eleanor R.
 CORPORATE SOURCE: May & Baker Ltd., Dagenham, UK
 SOURCE: British Journal of Pharmacology and Chemotherapy (1959), 14, 467-75
 CODEN: BJPCAL; ISSN: 0366-0826
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB Comps. related to N-(p-aminophenoxyalkyl)amide were prepared, and 102 were screened for schistosomicidal activity. Two of these comps., N-[5-(p-aminophenoxy)pentyl]phthalimide (I) and N-[5-(p-aminophenoxy)pentyl]benzamide (II) were investigated in detail. Given orally, I was inactive against *Schistosoma mansoni* in monkeys, but both I and II were effective in mice and hamsters. II was more toxic in rats, guinea pigs, and monkeys than I. Visual impairment in monkeys and cats by both comps. was considered to be less than other *p*-aminophenoxyalkyl derivs. not containing an amide group. Results of absorption studies of the 2 comps. in rats and mice show lower blood concentration after 4 hrs. Most of the drug was excreted in the 1st 24 hrs. I has been found to be moderately effective against *S. haematobium* infections in Africans.
 IT 103758-22-1, Phthalimide, N-[5-[p-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenoxy]pentyl]- (pharmacology of)
 RN 103758-22-1 CAPLUS
 CN Phthalimide, N-[5-[p-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenoxy]pentyl]- (6CI) (CA INDEX NAME)




ACCESSION NUMBER: 1960:38924 CAPLUS
 DOCUMENT NUMBER: 54:38924
 ORIGINAL REFERENCE NO.: 54:7613f-1, 7614a-1, 7615a-1, 7616a-1, 7617a-1, 7618a-1
 TITLE: Chemotherapy of schistosomiasis. III. N-(p-amino-phenoxyalkyl)amides, -imides, and -sulfonamides
 AUTHOR(S): Ashley, J. N.; Collins, R. F.; Davis, M.; Sirett, N. E.
 CORPORATE SOURCE: May & Baker, Dagenham, UK
 SOURCE: Journal of the Chemical Society (1959) 3880-94
 CODEN: JCSOAS; ISSN: 0368-1769
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB cf. C.A. 53, 17942c. Many acyl- and diacylaminoalkyl ethers of *p*-aminophenol (I) were prepared by a number of routes. Some of these comps.

were effective against schistosomides. *K* *p*-nitrophenoxide and 2-phthalimidoethyl bromide gave 221 1-(*p*-nitrophenoxy)-2-phthalimidoethane, m. 152-4° (AcOH). Similarly prepared in either alc. or EtOCH₂-CH₂OH were: 441 1-(*p*-nitrophenoxy)-3-phthalimidopropane, m. 189-91.5° (dioxane); 641 1-(*p*-nitrophenoxy)-4-phthalimidobutane, m. 119° (AcOH); 601 1-(*p*-nitrophenoxy)-10-phthalimidodecane, m. 102-3° (AcOH); and 551 1-(*p*-nitrophenoxy)-6-phthalimido-3-hexene (from 6-phthalimido-1-(*p*-toluenesulfonyloxy)-3-hexene), m. 118-19° (aqueous AcOH). 1-(*p*-Nitrophenoxy)-5-phthalimidopentane (IIa) treated with aqueous

N₂H₄. H₂O in alc. and the amine liberated by shaking the complex with CHCl₃ and warm 2N NaOH gave 1-amino-5-(*p*-nitrophenoxy)pentane (II), b.p. 160-5°. Similarly prepared were: 941 1-amino-5-(*p*-aminophenoxy)pentane, m. 67-9° (ligroine) (dimethanesulfonate m. 244-6°); and 911 1-(*p*-acetamidophenoxy)-5-aminopentane (IIa) m. 137-9° (C₆H₆) (methanesulfonate m. 155-7°). II (22.4 g.) and 28.6 g. tetrachlorophthalic anhydride heated 2 hrs. at 180-90°, cooled, and dissolved in 150 ml. hot EtOCH₂CH₂OH gave 96 1-(*p*-nitrophenoxy)-5-tetrachlorophthalimidopentane, m. 165-7°. Similarly prepared were: 841 1-(*p*-nitrophenoxy)-5-(3-nitrothiophthalimidopentane, m. 163-4.5°; 671 1-(*p*-acetamidophenoxy)-5-(3-nitrothiophthalimidopentane, m. 132-4° (alc.); and 651 1-homophthalimido-5-(*p*-nitrophenoxy)pentane, m. 144-5° (Me₂CO). 1-(*p*-Nitrophenoxy)-5-ureidopentane (61 g.), 24 g. CH₂(CO₂H)₂, and 55 ml. AcOH heated to 70-80°, treated dropwise with 45 ml. Ac₂O, left 8 hrs. at 90°, cooled, diluted with 84 ml. H₂O, and filtered gave a solid, m. 178.5-80.0°, possibly an Ac derivative. Further dilution with 240 ml. H₂O gave 1-[5-(*p*-nitrophenoxy)pentyl]barbituric acid, m. 149-51° (alc.). II (45 g.) and 15.2 g. Me salicylate heated 5 hrs. at 120°, dissolved in CHCl₃, washed with 2N HCl, dried, and evaporated gave 731 1-(*p*-nitrophenoxy)-5-(salicylamido)pentane (III), m. 123-5° (C₆H₆). ClCO₂Et (12 g.) slowly added to a cold solution of 35 g. III in 120 ml. C₆H₆, the mixture heated 2 hrs. at 100°, cooled, and diluted with H₂O gave 661 3,4-dihydro-3-[5-(*p*-nitrophenoxy)pentyl]-2,4-dioxo-5,6-benz-1,2-oxazine, m. 145-6° (AcOH and alc.). 5-(*p*-Nitrophenoxy)pentyl bromide (IIII) (16.15 g.), 10.15 g. (2)-camphorimide, 5.4 ml. 10.4N KOH, and 25 ml. EtOCH₂CH₂OH refluxed 2 hrs. and the product crystallized gave 711 1-camphorimido-5-(*p*-nitrophenoxy)pentane, m. 66-7° (aqueous alc.). N-[5-(*p*-Nitrophenoxy)pentyl]phthalhydrazide was similarly obtained in 23% yield, m. 160-2° (PhMe). II (22.4 g.) in 100 ml. CHCl₃ refluxed 1 hr. with 9.8 g. maleic anhydride in 100 ml. CHCl₃ gave 531 1-(*p*-carboxyacrylamido)-6-(*p*-nitrophenoxy)pentane (IV), m. 91-3° (alc.). Similarly prepared were: 631 1-(*p*-acetamidophenoxy)-5-

(*p*-carboxyacrylamido)pentane, m. 161-3° (aq. AcOH); 1-(*p*-carboxymethyl-*p*-methylvalerimido)-5-(*p*-nitrophenoxy)pentane (not obtained cryst.); and 921 1-(*p*-carboxybutyramido)-5-(*p*-nitrophenoxy)pentane (VI), m. 116-17°. IV (17.2 g.), 18 ml. Ac₂O, and 1.8 g. freshly fused NaOAc stirred 1 hr. at 100° gave 511 1-maleimido-5-(*p*-nitrophenoxy)pentane, m. 105-7° (ligroine). The glutaric acid (37.3 g.) and 100 ml. AcCl refluxed 20 min., evapd., and the residue crystd. gave 541 1-glutarimido-5-(*p*-nitrophenoxy)pentane, m. 87-8° (MeOH). 1-(*p*-Ethyl-*p*-methylglutarimido)-5-(*p*-nitrophenoxy)pentane was made similarly, but was not obtained cryst. Glutarimide (11.3 g.) and 28.8 g. 5-(*p*-nitrophenoxy)pentyl bromide refluxed 20 hrs. with 2.3 g. Na in 150 ml. alc., dild. with H₂O, and extd. with CHCl₃ gave 391 1-(*p*-ethoxycarbonylbutyramido)-5-(*p*-nitrophenoxy)pentane (VI), m. 90-1.5° (C₆H₆). Hydrolysis of VI with 1 equiv. 2N NaOH gave 931 V. When a similar condensation was carried out by using 1 equiv. of NaOH in aq. alc. 331 5-(*p*-nitrophenoxy)pentyl glutaramate (VII), m. 93-5° (C₆H₆), was obtained identical with a specimen prepd. in 34% yield from 5-(*p*-nitrophenoxy)pentyl bromide and Ag glutaramate in dry dioxane. Its structure was confirmed by catalytic redn. of VII to 811 5-(*p*-aminophenoxy)pentyl glutaramate, m. 116-18°, and subsequent hydrolysis to 5-(*p*-aminophenoxy)pentanol, m. 94-5°. The following *p*-C₆H₄(CO)₂NHRI (VIII) were prepd. from IIa, 1-amino-4-(*p*-nitrophenoxy)butane, II, or 1-amino-8-(*p*-nitrophenoxy)octane with the appropriate acid chloride or anhydride either in C₆H₅N or under Schotten-Baumann conditions (n, R, R', & yield, m.p., and solvent of recrystn. given): 4, NO₂, Bz, 82, 102-3°, aq. AcOH; 5, NO₂, *p*-BrC₆H₄CO, 81, 153-4°, alc.; 5, NO₂, *p*-MeC₆H₄CO, 73, 132-3°, AcOH; 5, NO₂, *p*-O₂NC₆H₄CO, 49, 148-50°, Me₂CO; 5, NO₂, *p*-AcOC₆H₄CO, 54, 131-3°, Me₂CO; 5, NO₂, *p*-HOC₆H₄CO, 91, 147-50°, PhMe; 5, NO₂, *o*-MeO₂CC₆H₄CO, 61, 140-1°, C₆H₆; 5, NO₂, *p*-MeO₂CC₆H₄CO, 56, 164-6°, alc.; 5, NO₂, *p*-MeSO₂CC₆H₄CO, 22, 169-71°, AcOH; 5, NO₂, hexahydrobenzoyl, 87, 123°, AcOH; 5, NO₂, EtCO, 69, 79-80°, aq. alc.; 5, NO₂, C₆H₅ICO, 60, 59-60°, Et₂O; 5, NO₂, Ph₂CHCO, 53, 104-6°, aq. Me₂CO; 5, NO₂, Ph(CH₂)₄CO, 82, 87-9°, aq. alc.; 5, NO₂, 2,4-Cl₂C₆H₃COCH₂CO, 37, 112-14°, alc.; 5, NO₂, C₆H₄(CO)₂NC₂H₂CO, 68, 183.5-5.0°, EtO(CH₂)₂OH; 5, AcNH, *p*-O₂NC₆H₄CO, -, 214-17.5°, alc. or EtO(CH₂)₂OH; 5, NO₂, PhSO₂, 71, 73-5°, alc.; 5, NO₂, *p*-MeC₆H₄SO₂, 93, 154-6°, aq. alc.; 5, NO₂, *p*-AcNH₂CC₆H₄SO₂, 77, 129-31°, aq. alc. N,N'-Bis[5-(*p*-nitrophenoxy)pentyl]terephthalamide (581), m. 154-7° (alc.), and 391 N,N'-bis[5-(*p*-nitrophenoxy)pentyl]glutaramide (591), m. 127-9° (Me₂CO), were similarly prepd. II and NCCCH₂CO₂Et in refluxing alc. gave 681 1-cyanoacetamido-5-(*p*-nitrophenoxy)pentane, m. 85-6° (aq. alc.). Similarly obtained in the absence of solvent was 731 N,N'-bis[5-(*p*-nitrophenoxy)pentyl]oxamide, m. 163.5-4.5° (CHCl₃-alc.). Ethoxalyl chloride (13.65 g.) slowly added to 21.4 g. II in 100 ml. C₆H₅N, the soln. kept overnight at room temp., dild. with H₂O and Et₂O, and filtered gave 271 1-ethoxalylamino-5-(*p*-nitrophenoxy)pentane, m. 85-7° (ligroine), II (26.4 g.), 13.95 ml. concd. HCl, and 64.5 g. RCONH₂ heated 0.5 hr. at 145°, cooled, evapd., 100 ml. H₂O added, and the crude product extd. with Et₂O in a Soxhlet app. gave 781 1-formamido-5-(*p*-nitrophenoxy)pentane, m. 71-2°. 2-Phenylloxazoline (8.2 g.) added to 12 g. II in CHCl₃, the solvent evapd., and the residue heated 0.5 hr. at 100° gave 801 1-hippuramido-5-(*p*-nitrophenoxy)pentane, m. 45-7° (alc.). Ia (17.7 g.) refluxed 15 min. with 50 ml. N NaOH gave 1-*o*-carboxybenzamido-5-(*p*-nitrophenoxy)pentane, m. 118-22° (CHCl₃-ligroine). Tetra-Et pyrophosphate (2.7 ml.) added to 2.24 g. II and 1.79 g. *p*-acetamidobenzoic acid in 7 ml. di-Et phosphite, the mixt. heated 1 hr. at 100°, dild. with H₂O, and cooled gave 551 1-(*p*-acetamidobenzamido)-5-(*p*-


L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 103758-22-1 CAPLUS
 CN Phthalimide, N-[5-[p-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenoxy]pentyl
]- (6CI) (CA INDEX NAME)



RN 111978-34-8 CAPLUS
 CN 2-[5-[p-[(2-Amino-6-methyl-4-pyrimidinyl)amino]phenoxy]pentyl]-2-methyl-
 1,3-dioxolimidinium methyl sulfate (6CI) (CA INDEX NAME)

CH 1

CRN 111978-33-7
 CMF C25 H28 N5 O3



CH 2

CRN 21228-90-0
 CMF C H3 O4 S


Me-O-SO3-

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1957:61796 CAPLUS
 DOCUMENT NUMBER: 51:61796
 ORIGINAL REFERENCE NO.: 51:11197a-g
 TITLE: Geology of the Nokia region, Southwest Finland
 AUTHOR(S): Marmo, Vladi
 CORPORATE SOURCE: Geol. tutkimuslaitos, Otoniemi
 SOURCE: Bull. comm. geol. Finlande (1957), No. 176, 38 pp.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The rocks of the Nokia area comprise phyllites and related rocks, Ca-rich
 schists, limestone, and dikes of diabase and tremolite-actinolite rock.
 Many aspects of the geology of the region are reviewed. The occurrence of
 trace elements (Zn, Ni, V, Cu, Mo, Cr, B) in the schists and other rocks
 is discussed. An account is given of the manner of origin of the rocks
 and their metamorphic facies. Two new chemical analyses of a
 tremolite-actinolite vein rock are given. 37 references.

IT 93001-35-5
 (Derived from data in the 6th Collective Formula Index (1957-1961))


RN 93001-35-5 CAPLUS
 CN Pyrimidine, 2-amino-4-p-anisidino-6-methyl- (7CI) (CA INDEX NAME)



L4 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1957:17528 CAPLUS
 DOCUMENT NUMBER: 51:17528
 ORIGINAL REFERENCE NO.: 51:3675b-d
 TITLE: 1-(4-Anilino-2-pyrimidinyl)-3-alkylureas
 INVENTOR(S): Burtner, Robert R.
 PATENT ASSIGNEE(S): G.D. Searle and Co.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2748124		19560529	US 1954-428136	19540506


AB 1-(4-(N,4-Disubstituted anilino)-2-pyrimidinyl)-3-ethylureas (I) (the
 substituents = R and Y, resp., where Y is H and lower alkoxyl radicals
 containing less than 3 C atoms, and R is H and lower alkyl radicals
 containing less than 3 C atoms) are prepared from a 2-amino-4-halopyrimidine treated
 with aniline or a substituted aniline to give the 4-anilino-2-
 aminopyrimidine (II), and II is treated with an alkyl isocyanate in PhMe
 or dioxane at 85-120° to yield I. The I are useful in the field of
 cardiac pathology, showing digitalis-like activity. 2-Amino-4-
 chloropyrimidine (III) 43, PhNHET 133, HCl 13, and in H2O 1100 parts (all
 by weight) refluxed 30 min., the mixture cooled, made alkaline with an
 excess of
 50% aqueous NaOH, and the solidified oil rinsed with H2O, dried at 75°,
 and crystallized from approx. 5 vols. PhMe with decolorizing C yield
 2-amino-4-(N-ethylanilino)pyrimidine (IV), white crystals, m.
 142-4°. IV 41, EtNCO approx. 14, and dry PhMe 435 parts refluxed
 12 hrs., the mixture chilled, filtered, and the crystalline product rinsed
 with
 PhMe, dried at 75° and recrystd. from 10 vols. EtOH yield white I
 (Y = H, R = Et), m. 186-7°. Similarly III, p-phenetidine, and HCl
 yield colorless 2-amino-4-(p-phenetidino)pyrimidine (V), m. approx.
 163° (from EtOH). V and EtNCO in dioxane yield I (Y = EtO, R = H),
 feathery white needles, m. approx. 218° (from EtOH).
 IT 100120-45-4P, Pyrimidine, 2-amino-4-p-phenetidino-
 RL: PREP (Preparation)
 (preparation of)
 RN 100120-45-4 CAPLUS
 CN Pyrimidine, 2-amino-4-p-phenetidino- (6CI) (CA INDEX NAME)



L4 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1955:60839 CAPLUS
 DOCUMENT NUMBER: 49:60839
 ORIGINAL REFERENCE NO.: 49:11726h-1, 11727a-b
 TITLE: 2-Amino-4-substituted amino-6-arylpyrimidines
 INVENTOR(S): Hitchings, Geo. H.; Russell, Peter B.
 PATENT ASSIGNEE(S): Burroughs Wellcome and Co. (U.S.A.) Inc.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2691655		19541012	US 1952-289907	19520524

AB 2-Amino-4-substituted amino-6-arylpyrimidines, useful as growth inhibitors
 for rapidly growing virus are prepared from the corresponding
 4-hydroxypyrimidine by conversion to the 4-chloropyrimidine and subsequent
 reaction with the appropriate amine. Thus, 47 g. BzCHPrCO2Et, refluxed 6
 hrs. with 12 g. guanidine carbonate in 200 ml. EtOH, gives
 2-amino-4-hydroxy-5-propyl-6-phenylpyrimidine (I), m. 311-13°,
 obtained by dilution of the reaction mixture with 500 ml. H2O and recrystn.
 of
 the precipitate from EtOH; the 5-benzyl analog (II), m. 340°, was prepared
 similarly from BzCH(CH2Ph)CO2Et. Refluxing 10 g. I with 50 ml. POCl3
 until solution was achieved, removing the excess POCl3, and suspending the
 residue in iced aqueous NH4OH gave 2-amino-4-chloro-5-propyl-6-
 phenylpyrimidine (III). Similarly, II yields the 5-benzyl analog (IV) of
 III; heating 5 g. III with 100 ml. of a saturated solution of MeNH2 in EtOH
 in a
 bomb for 16 hrs. at 150° gives 4.2 g. 4-MeNH analog of III, m.
 198°, and IV gives the 4-MeNH analog of IV, m. 177°.
 Refluxing 5 g. III with 25 ml. of PhNH2 5 hrs., cooling, and recrystg. the
 precipitate from EtOH, gives needles of the 4-PhNH analog of III, m. 171°;
 4-PhNH analog of IV, m. 211°. The following compds. are obtained
 by analogous procedures: 2-amino-4-methylamino-6-(2-naphthyl)pyrimidine,
 m. 238-9°; 2-amino-4-methylamino-6-phenylpyrimidine, m.
 195-6°, and its 4-PhNH, m. 305-6° (decomposition),
 4-(p-ClC6H4NH), m. 304-5°, and 4-(p-MeOC6H4NH) analogs, m.
 259-63°.
 IT 875233-37-7P, Pyrimidine, 2-amino-4-p-anisidino-6-phenyl-
 RL: PREP (Preparation)
 (preparation of)
 RN 875233-37-7 CAPLUS
 CN Pyrimidine, 2-amino-4-p-anisidino-6-phenyl- (5CI) (CA INDEX NAME)




L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 1954:7533 CAPLUS
DOCUMENT NUMBER: 48:7533
ORIGINAL REFERENCE NO.: 48:1445e-1
TITLE: Therapeutically useful pyrimidines
PATENT ASSIGNER(S): Burroughs Wellcome & Co. (U.S.A.) Inc.; Wellcome Foundation Ltd.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 681712		19521029	GB 1949-23768	19490914

GI For diagram(s), see printed CA issue.

AB Physiologically active compounds were prepared, represented by $\text{N}(\text{C}(\text{NH}_2)\text{N}(\text{CR}_3)\text{CR}_2\text{CR}_1)$ (I) where R1 is Ph, 2-ClOH7, p-ClC6H4, p-BrC6H4, or p-O2NC6H4; R2 is H, PhCH2, or straight- or branched-chain alkyl radical of not more than 7 C atoms; and R3 is NH2, straight- or branched-chain alkyl amino of not more than 7 C atoms, or a MeOC6H4NH, PhCH2NH, PhNH, p-ClC6H4NH, p-BrC6H4NH, p-MeOC6H4NH, or p-EtOC6H4NH, Cl, or HO. The compounds were prepared from the p-HO derivs. (prepared by refluxing guanidine carbonate in alc. with the appropriate oxo ester), which were converted to the corresponding Cl derivs. with POCl3, and the Cl derivative, treated with the corresponding amine gave I (R3 = NHR). The following I (R1, R2, R3, and m.p. given) are disclosed: Ph, H, Cl, 148° (from aqueous EtOH); Ph, H, NH2, 162° (from EtOH); Ph, Me, HO, 287° (Ph, Me, Cl, 127-8°; Ph, Me, NH2, 196-7° (from EtOH); Ph, Pr, HO, decompose 311-13°; Ph, Pr, Cl, -; Ph, Pr, NH2, 165-6° (from aqueous EtOH); Ph, PhCH2, HO, decompose 334° (from EtOH); Ph, PhCH2, Cl, -; Ph, PhCH2, NH2, 222-3° (from aqueous EtOH); Ph, H, NHMe, 195-6° (from H2O); Ph, H, NHPh, decompose 305-6° (from HOAc); Ph, H, p-ClC6H4NH, 304-5° (from HOAc); Ph, H, p-MeOC6H4NH, 259-63° (from HOAc); p-ClC6H4, H, HO, decompose 344-7° (from HOAc); p-ClC6H4, H, Cl, -; p-ClC6H4, H, NH2, 161-2° (from aqueous EtOH); p-ClC6H4, Me, HO, 331-3° (from aqueous EtOH); p-ClC6H4, Me, Cl, -; p-ClC6H4, Me, NH2, 184-5° (from aqueous EtOH); p-O2NC6H4, H, HO, decompose 334° (from HOAc); p-O2NC6H4, H, Cl, -; p-O2NC6H4, H, NH2, decompose 239° (from EtOH); 2-ClOH7, H, HO, -; 2-ClOH7, H, Cl, -; 2-ClOH7, H, NH2, 205-6° (from aqueous EtOH); 2-ClOH7, H, NHMe, 238-9° (from aqueous EtOH).

IT 875233-37-7P, Pyrimidine, 2-amino-4-p-anisidino-6-phenyl-
RI: PREP (Preparation)
(preparation of)
RN 875233-37-7 CAPLUS
CN Pyrimidine, 2-amino-4-p-anisidino-6-phenyl- (5CI) (CA INDEX NAME)




L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
and 100 cc. HCl, refluxed 1 hr., give 16.3 g. 4-chloro-6-hydroxy-2,5-dimethylpyrimidine (XII), m. 225° (XII (25 g.) and 18.3 g. Et2NCH2CH2NH2, heated 8 hrs. at 150-60°, give 4-(2-diethylaminoethylamino)-6-hydroxy-2,5-dimethylpyrimidine (characterized as the dipicrate, yellow, m. 154°); refluxed 5 hrs. with POCl3, there results 21.9 g. 4-chloro-6-(2-diethylaminoethylamino)-2,5-dimethylpyrimidine (XIII), b.p. 0.85 139°; hydrate m. 80°; dipicrate, yellow, m. 143° (XIII (31.7 g.) and 31.6 g. Et2N(CH2)3CH2NH2, heated 8 hrs. at 150-60°, give 4-(4-diethylamino-1-methylbutylamino)-6-hydroxy-2,5-dimethylpyrimidine, whose HCl salt (XIII) could not be crystd.; dipicrate m. 163-4°; 62 g. crude XIII and 225 cc. POCl3, refluxed 4 hrs., give 22.05 g. 4-chloro-6-(4-diethylamino-1-methylbutylamino)-2,5-dimethylpyrimidine, b.p. 0.55 144-5° (a cryst. deriv. could not be prepd.). X (14.6 g.), 15 g. Et2NCH2CH2NH2, and a trace of XI, heated 6 hrs. at 150-60°, give 11.6 g. 4-p-chloroanilino-6-(2-diethylaminoethylamino)-2,5-dimethylpyrimidine (XIV), b.p. 0.7 209°; di-HCl salt m. 263-4°; it results also (5.7 g. yield) on heating 5.13 g. XII, 3.28 g. p-ClC6H4NH2.HCl, and 0.25 cc. HCl 6 hrs. at 150-60°.

6-(3-diethylaminopropylamino) analog of XIV m. 105°; di-HCl salt m. 275-6° (decompn.). 6-(4-diethylamino-1-methylbutylamino) analog of XIV b.p. 55 208° (cryst. derivs. could not be prepd.). XII (10.26 g.), 6.9 g. p-BrC6H4NH2.HCl, and a few drops HCl, heated 6 hrs. at 150-60°, give 4-p-bromoanilino-6-(2-diethylaminoethylamino)-2,5-dimethylpyrimidine, whose di-HCl salt m. 265-6°; IX (5.31 g.), 4.5 g. p-MeOC6H4NH2, 30 cc. AcOH, and 0.2 g. 10 N HCl, stirred 20 hrs. at 40-5°, 4 g. AcONa added, and the soln. dild. with 300 cc. H2O, give 6.4 g. 4-chloro-6-p-methoxyanilino-2,5-dimethylpyrimidine (XV), m. 201°; XV results in 9.5 g. yield from 8.85 g. IX, 6.15 g. p-MeOC6H4NH2, 40 cc. H2O, 20 cc. Me2CO, and 1 cc. 10 N HCl on refluxing 3 hrs. XV (10 g.), 14 g. Et2NCH2CH2NH2, and a trace of XI, heated 6 hrs. at 150-60°, give 8.9 g. 4-p-methoxyanilino-6-(2-diethylaminoethylamino)-2,5-dimethylpyrimidine, b.p. 5 203°; di-HCl salt, with 1 mol. H2O, m. 254-5°; IX (5.22 g.), 4.55 g. p-O2NC6H4NH2, 50 cc. AcOH, and a little KI, heated 18 hrs. at 55-60°, give 5.2 g. 4-chloro-6-p-nitroanilino-2,5-dimethylpyrimidine (XVI), yellow, m. 208-10°; XII (1 g.) and 0.68 g. p-O2NC6H4NH2.HCl, heated 6 hrs. at 150-60°, give 4-p-nitroanilino-6-(2-diethylaminoethylamino)-2,5-dimethylpyrimidine, yellow, m. 104-6°; di-HCl salt, yellow, m. 254-6°; the base results in 1.8 g. yield on heating 1.8 g. XVI, 1.8 g. Et2NCH2CH2NH2, and a trace of XI 5 hrs. at 155-65°. 4,6-Dihydroxy-2-methyl-5-ethylpyrimidine (30 g.) and 110 cc. POCl3, refluxed 2 hrs., give 4,6-dichloro-2-methyl-5-ethylpyrimidine (XVII), b.p. 212-14°, 25 g. XVII, 100 cc. HCl, and 250 cc. H2O, refluxed 2.5 hrs., give 19.2 g. 4-chloro-6-hydroxy-2-methyl-5-ethylpyrimidine (XVIII), m. 200°. XVIII (8.63 g.), 9.6 g. p-ClC6H4NH2, and 0.5 cc. HCl, heated 8 hrs. at 160-70°, give 8.1 g. 4-p-chloroanilino-6-hydroxy-2-methyl-5-ethylpyrimidine (XIX), m. 275°; XVII (5.73 g.) and 4.3 g. p-ClC6H4NH2 in 30 cc. AcOH contg. a crystal of KI, stirred 20 hrs. at 35-45°, give 4-chloro-6-p-chloroanilino-2-methyl-5-ethylpyrimidine (XX), m. 166°; XX was prepd. also by refluxing 8.9 g. XIX and 45 cc. POCl3 1.5 hrs. XVIII (34.5 g.) and 26 g. Et2N(CH2)3NH2, heated 8 hrs. at 150-60°, give 4-(3-diethylaminopropylamino)-6-hydroxy-2-methyl-2-ethylpyrimidine (XXI), characterized as the dipicrate, yellow, m. 188°; 59.5 g. of the HCl salt of XXI and 225 cc. POCl3, refluxed 15 hrs., give 4-chloro-6-(3-diethylaminopropylamino)-2-methyl-5-ethylpyrimidine, b.p. 5 142° (dipicrate yellow, m. 147-8°). XX (2 g.), 2 g. Et2NCH2CH2NH2, and a little KI, heated 6 hrs. at 140-50°, give 4-p-chloroanilino-6-(2-diethylaminoethylamino)-2-


L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 1948:5794 CAPLUS
DOCUMENT NUMBER: 42:5794
ORIGINAL REFERENCE NO.: 42:12721,1273a-1,1274a-1,1275a-h
TITLE: Synthetic antimalarials. XXI. 4-Arylamino-6-(aminoalkylamino)pyrimidines. Further variations
AUTHOR(S): Basford, F. R.; Curd, F. H. S.; Hoggarth, E.; Rose, F. L.
CORPORATE SOURCE: Imperial Chem. Industries Ltd., Manchester, UK
SOURCE: Journal of the Chemical Society (1947) 1354-64
CODEN: JCSO99; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

GI For diagram(s), see printed CA issue.

AB Cf. C.A. 42, 187c. This is a continuation of the work reported in C.A. 41, 131b. In that work it was pointed out that, in compds. of type I (R = dialkylaminoalkyl, R' = p-ClC6H4NH), there do not exist 2 amidine units capable of independent tautomerism as are found in the 2 isomeric types (II and III). Since one important development (C.A. 41, 134b) was in part based on the recognition of the possible significance of this difference, it was desirable to demonstrate, with as much certainty as possible, that antimalarial activity could not be developed in compds. of type I. 4-Chloro-6-hydroxy-2-methylpyrimidine (IV) (14.4 g.) and 11.6 g. Et2NCH2CH2NH2, heated 8 hrs. at 150-60°, give the 4-(2-diethylaminoethylamino) derivative, whose HCl salt (V) (with 1 mol. lost at 100°) m. 193-5°; 20 g. V and 75 cc. POCl3, refluxed 3 hrs., give 9.9 g. 4-chloro-6-(2-diethylaminoethylamino)-2-methylpyrimidine (VI), b.p. 15 136-7° (dipicrate, yellow, m. 144-5°). 4-(3-diethylaminopropylamino) analog of V (with 1.5 mols. H2O, 1 of which is lost at 100°) m. 87-9° (air-dried) or 186-8° (dried at 100°); 6-(3-diethylaminopropylamino) analog (VII) of VI b.p. 15 143-5° (dipicrate, yellow, m. 158-9°). VI (4.85 g.), 2.55 g. p-ClC6H4NH2, 25 cc. H2O, and 2.2 cc. 10 N HCl, refluxed 6 hrs., give 86.2% 4-p-chloroanilino-6-(2-diethylaminoethylamino)-2-methylpyrimidine (VIII), m. 148° (C.A. 41, 131b); VII gives the 6-(3-diethylaminopropylamino) analog, m. 129-31°; IV (28.9 g.) and 31.6 g. Et2N(CH2)3CH2NH2, heated 8 hrs. at 150-60°, 180 cc. POCl3 added to the cooled reaction, and the mixture refluxed 3 hrs., give 36.4 g. 4-chloro-6-(4-diethylamino-1-methylbutylamino)-2-methylpyrimidine, b.p. 125 168-70° (dipicrate, yellow, m. 171-3°); treated with p-ClC6H4NH2 as above, this yields the 6-(4-diethylamino-1-methylbutylamino) analog of VIII, b.p. 15 220-5°; the dipicrate m. 159-61° (previously reported as 149-51°); the 2 compds. are probably dimorphous; the conditions for obtaining the 2 forms were not fully elucidated). 2-Chloro-4-amino-6-methylpyrimidine (7.2 g.), 6.4 g. p-ClC6H4NH2, 25 cc. H2O, and 0.5 cc. 10 N HCl, refluxed 1 hr., give 2-amino-2-p-chloroanilino-6-methylpyrimidine, b.p. 5 190-2°, m. 121-2°; this also results on heating 10 g. 4-chloro-2-p-chloroanilino-6-methylpyrimidine and 30 cc. NH4OH 12 hrs. at 140-50°. Similarly 4-chloro-2-amino-6-methylpyrimidine yields the 4-p-chloroanilino analog, m. 216-18°; this results also on heating 5 g. 4-chloro-2-(p-chlorophenylguanidino)-6-methylpyrimidine and 25 cc. saturated EtOH-NH3 12 hrs. at 175°. 4-Chloro-6-amino-2-methylpyrimidine (7.2 g.), 6.4 g. p-ClC6H4NH2, 25 cc. H2O, and 0.5 cc. 10 N HCl, refluxed 1 hr., give 4-amino-6-p-chloroanilino-2-methylpyrimidine, m. 159-61°; 4,6-Dichloro-2,5-dimethylpyrimidine (IX) (8.85 g.), 6.4 g. p-ClC6H4NH2, 40 cc. H2O, and 2 cc. 10 N HCl, refluxed 2 hrs., give 9.9 g. 4-chloro-6-p-chloroanilino-2,5-dimethylpyrimidine (X), m. 176-7°; X results also on heating 5.3 g. IX and 4.2 g. p-ClC6H4NH2 in 30 cc. AcOH containing a crystal of KI 20 hrs. at 40°. IX (25 g.), 250 cc. H2O,




RN 056971-31-B CAPLUS
CN Pyrimidine, 2-amino-4-p-anisidino-6-chloro-, hydrochloride (5CI) (CA INDEX NAME)



● HCl

LA ANSWER 35 OF 35 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1944:33307 CAPLUS
 DOCUMENT NUMBER: 38:33307
 ORIGINAL REFERENCE NO.: 38:4952h-1, 4953a-b
 TITLE: Arylaminoheterocyclic compounds. II.
 Arylaminoypyrimidines
 AUTHOR(S): Banks, C. Kenneth
 SOURCE: Journal of the American Chemical Society (1944), 66,
 1131
 CODEN: JACSAT ISSN: 0002-7863
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB PhNH2 and 2-amino-4-chloropyrimidine (0.1 mol each) and 1 mL HCl in 100
 mL H2O, refluxed 30 min. and the product made strongly alkaline with 10 N
 NaOH, give 92% of 2-amino-4-anilinoypyrimidine, m. 155-6° (m. ps.
 corrected); solution in glacial AcOH and precipitation with ether give the
 diacetate, heating,
 170°, heating, in vacuo, or solution of the base in dilute AcOH gives
 the monoacetate, m. 176-8°, alc. HCl with addition of 5 vols. AcOBu
 gives the HCl salt, m. 184-5°. The following 4 substituted
 2-aminopyrimidines were similarly prepared: 2,6-dimethylanilino, m.
 186-7°, 4-phenylanilino, m. 193-5°; 2-isomer, m.
 130-2°; 1-naphthylanilino, m. 133-4°; morpholino, m.
 157-61°; 4-acetylanilino-HCl, m. 275-6°
 4-acetamidooanilino-HCl, m. 299-300°; 3,4-dimethoxyanilino-HCl, m.
 270°; 4-methoxyanilino-HCl, m. 276-8°; 2,6-dihydroxyanilino-
 2HCl, m. 123-4°; 2-hydroxyanilino-2HCl, m. above 200°;
 3-isomer-HCl, m. 178-80°; 4-isomer, m. 245-7° (decomposition)
 (HCl salt, m. 275-7°); 4-carboxyanilino, m. 295-7°
 (decomposition) (diethyaminomethanol ester-3HCl, m. above 250°);
 2-carboxyanilino (Na salt), m. above 250°. 4-Amino-2-
 anilinoypyrimidine-HCl, m. 149-50°; 2-amino-4-anilino-6-
 methylpyrimidine, m. 170-2°; 2,4-dianilinoypyrimidine, m.
 136-8° (HCl salt, m. 194-5°).
 IT 857628-04-7, Phenol, p-(2-amino-4-pyrimidinylamino)-
 (hydrochlorides)
 RN 857628-04-7 CAPLUS
 CN Phenol, p-(2-amino-4-pyrimidinylamino)- (4CI) (CA INDEX NAME)




```

IT 861031-85-8P, Pyrimidine, 2-amino-4-p-methoxyanilino-, -HCl
RL: PREP (Preparation)
    (preparation of)
RN 861031-85-8 CAPLUS
CN Pyrimidine, 2-amino-4-p-methoxyanilino-, -HCl (4CI) (CA INDEX NAME)

```

L4 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

=> d his

(FILE 'HOME' ENTERED AT 11:44:44 ON 26 JUL 2007)

FILE 'REGISTRY' ENTERED AT 11:44:56 ON 26 JUL 2007

L1 STRUCTURE UPLOADED
L2 18 S L1
L3 411 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:46:03 ON 26 JUL 2007

L4 35 S L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

185.86

358.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

TOTAL
SESSION

CA SUBSCRIBER PRICE

-27.30

-27.30

STN INTERNATIONAL LOGOFF AT 11:48:04 ON 26 JUL 2007